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Solid  organ  transplant  has  emerged  over  the  last  half  century  as  an  important 
treatment for solid organ failure. Management has matured dramatically over the past two 
decades with improvements in acute rejection, but long-term graft survival has improved very 
little and current treatment is limited by the side-effects and toxicities of immunosuppressive 
medications. Nanoparticle delivery of therapeutics, improving transport characteristics and 
decreasing systemic and local toxicity has emerged as a dynamic treatment modality, but 
little work has been done using nanoparticles in transplantation. Our research examined the 
use of CD4-targeted nanoparticles encapsulated with mycophenolic acid (MPA), a commonly 
used immunosuppressant in organ transplantation. This work is the first to examine  antigen-
specific  targeting of  nanoparticles in any transplant  model.  MPA-loaded particles show a 
slow and continuous release profile and biodistribution suggested retention in the spleen. 
Targeting of nanoparticles to CD4 T cells was suggested using  ex vivo  and  in vitro flow 
cytometry.  In the  fully  allogeneic  MHCII  mismatch  BALB/C  to  C57BL/6  mice  we  found 
improved graft survival in the non-targeted MPA group and even greater graft survival in the 
CD4-targeted  group.  Targeted  and  non-targeted  particle  groups  showed  equal  delay  in 
rejection in the less immunogenic single MHC mismatch B6.H-2bm12 to C57BL/6 model that 
we showed to be CD4 dependent. In both models, graft survival times were increased over 
free drug and controls with roughly one thousand fold lower dose of drug in the nanoparticles 
as compared with free MPA.  Consistent with these findings were decreased proliferation 
with  targeted  and  non-targeted  MPA-nanoparticles  using  in  vitro and  ex  vivo mixed 
lymphocyte reactions. We postulated that the similar rejection times in targeted and non-
targeted groups was due to dendritic cell (DC) involvement and we found active uptake of 
nanoparticles in DCs, a decrease in inflammatory cytokine production and a decrease in 
treated DCs ability to stimulate T cells via mixed lymphocyte reactions.  Furthermore we 
found a possible mechanism in the DC interaction with T cells through the upregulation of the 
inhibiting  co-stimulatory  molecules  B7-DC  and  B7-H1  on  DCs  treated  with  MPA-
nanoparticles. We also found possible upregulation of CD4+CD25+ Foxp3 expressing Tregs 
which may serve to increase graft acceptance.  These results explore the involvement of 
dendritic  cells  in  the  process  of  nanoparticle-induced  graft  acceptance  and  suggest  the 
feasibility of using nanoparticle drug vectors in clinical transplant.
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Introduction
Solid organ transplantation in humans has emerged over the past few decades 
as a major advance in life-saving treatments for a number of diseases  (1),  (2).  Lung 
transplants  treat  incurable  cystic  fibrosis  (3) and  other  pulmonary  disorders,  heart 
transplants,  liver  and  kidney  transplants  treat  a  number  of  diseases  that  would 
eventually lead to patients death  (4).  Great advances have been made in the basic 
science understanding that we currently have of major and minor histocompatability, and 
the mechanisms of graft rejection.  These advances have helped to improve both graft 
survival and long-term recipient survival  (4).  Medical treatment of transplant rejection 
has been primarily through immunosuppressive drug modalities to delay acute rejection. 
While usually successful at initially maintaining graft survival, long-term survival is often 
limited by patients'  intolerance to the side-effects of  chronic  immunosuppression  (5). 
Increased susceptibility to opportunistic infections limits chronic treatments.  Additionally, 
immunosuppression leads to increased incidence of solid and hematologic neoplasms 
(6).   Direct  toxicity  of  these medications  can lead to  severe  hypertension,  diabetes, 
nephrotoxicity and many other severe complications and worsen the risk benefit ratio of 
long-term  treatments.   Therefore  improvements  in  immune  suppression  after  organ 
transplantation are clearly required.
With this in mind, the goal of treatment would be to reduce systemic toxicities and 
side-effects  while  maintaining  therapeutic  doses  to  the  organ  or  cell  population  of 
interest.   Traditional  treatment  modalities  use  systemic  delivery  and  generally  have 
narrow a therapeutic index.  With variable bio-absorption and bio-availability, traditional 
systemic delivery of drug often falls outside of this narrow index with difficulty balancing 
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efficacy and toxicity.  Moreover, the efficacy of systemic drug delivery is hampered by 
genetic  polymorphisms  (7),  up-regulation  of  drug  efflux  pumps  and  development  of 
resistance  (8).   With  these  problems as  the  driving  force,  nanoparticles  have  been 
utilized  as  a  method  of  encapsulating  toxic  drug,  allowing  specific  delivery  and 
decreasing side-effects.  
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Background
Transplantation
In the 2000's there have been between 13,000 to 17,000 kidney transplants per 
year in the US (9).  Liver transplants are the second most common with 5,000 to 7,000 
per  year.   Heart  transplants  are third most  common (1800-2300)  and lung is  fourth 
(1000-1500).  Other solid organs such as pancreas and intestine, as well as combined 
transplants (heart/lung or kidney/pancreas) are less common (9).  In 2008, only 6,000 of 
the 22,000 transplants were done with living donors, with the remaining from deceased 
donors, despite the dramatic difference in graft survival between living and deceased 
grafts (9).  
The first successful solid organ transplantation was a kidney allograft in 1954 (4). 
By the end of the 1960's, liver, lung, heart and pancreas transplantation was operatively 
successful as well, despite extremely poor post-operative graft and host survival.  In the 
mid 1970's cyclosporine was discovered by Jean Borel (10) and after approval in 1983 
became a major breakthrough in the medical management of transplantation (11).  Prior 
to  this  breakthrough,  post-op  survival  times  were  dismal  for  patients  receiving  solid 
organ allografts.  In the last twenty years our understanding of the immune system has 
allowed for human leukocyte antigen (HLA) typing and research has uncovered organ 
specific  responses  to  transplant  that  have  improved  management.   Organ  specific 
metrics and measures by which to follow transplant function and rejection have been 
developed as well, and further drug development has created more immunosuppressive 
medications  (4).   These  advances  have  continued  to  improve  post-transplantation 
survival of patients.  One study looked at changes in renal graft survival from 1988 to 
1998.   They found an improvement  from 89.7% to 94.3% one-year-survival  in  living 
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donors, and an improvement from 76.0% to 89.3% one-year-survival in cadaveric grafts. 
These improvements occurred despite the use of older donors (which generally worsens 
graft  function)  in  this  study.   There was also  an overall  decrease in  acute rejection 
episodes which can be an important predictor for late rejection (12).  Outcomes in other 
solid  organ  transplants  such  as  heart  and  liver  have  similarly  improved  as  medical 
management has evolved (4).
Transplant Rejection
There are generally three types of transplant rejection that are commonly seen: 
hyper-acute reactions immediately following reperfusion, acute rejection occurring days 
to years after surgery and chronic rejection that takes many years to manifest.  Hyper-
acute  rejection  occurs  within  minutes  of  the  transplantation  and  is  mediated  by 
preformed antibodies  against  the  tissue leading to  rapid  rejection.   ABO blood  type 
incompatibility is the most common cause of hyper-acute rejection, but it can also occur 
due to alloantibodies against major histocompatability complex (MHC) (Human leukocyte 
antigen or HLA is the human form of MHC).  Preformed antibodies bind to the graft and 
the complement cascade is triggered, leading to complement-mediated destruction of 
the  graft  tissue  (13).   The  blood  clotting  cascade  is  also  initiated  which  leads  to 
thrombosis and interruption of blood flow in the vascularized graft and tissue ischemia. 
In cases of hyper-acute rejection the graft  must immediately be removed in order to 
prevent  a  systemic  inflammatory  response.   This  type  of  rejection  is  generally 
preventable by careful HLA and ABO matching and measurements of allograft-specific 
antibodies, but is not acutely treatable (13)  
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Acute rejection occurs from weeks to years after the transplant surgery.  It  is 
generally thought  to be caused by HLA mismatch between graft  and host.   Even in 
carefully matched transplants, it is difficult to fully match all HLA types, and minor histo-
incompatibility  is  likely  present  even  in  the  best  HLA matches.   Acute  rejection  is 
common in all transplantation and does not usually lead to loss of the graft (14).  A single 
episode if treated promptly is not a cause of concern; however, recurrent episodes have 
been shown to lead to increases in chronic rejection.
Acute rejection unlike hyper-acute rejection is a T cell  dependent process.  T 
cells can be activated through a direct and an indirect pathway.  The indirect pathway 
occurs when host antigen presenting cells (APCs) such as dendritic cells, phagocytose 
foreign particles such as graft tissue.  The host APCs migrate to the lymph nodes and 
spleen and present  the foreign proteins via MHCII  to T cells  (Figure 1).   The direct 
pathway occurs when resident donor APCs within the graft directly display foreign self 
protein via MHC to host T cells (Figure 1).  In either pathway, the antigen specific T cell 
population is  activated and T cell  populations are increased that  will  target  the graft 
tissue.  CD8 cytotoxic T cells activated by MHCI and CD4 T cells activated by MHCII 
upregulate  the  inflammatory  response  through  macrophage  activation  as  well  the 
humoral response.  The direct pathway is thought to be more involved in acute rejection 
with direct T cell toxicity likely due to the higher frequency of directly allospecific T cells, 
but the indirect pathway is also involved in acute rejection.  Indirect activation causes  T 
cell  activation,  macrophage-induced  tissue  injury,  fibrosis  and  alloantibody  formation 
(15), (16) (13).  
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Chronic rejection occurs over very long periods of time leading to progressive 
vascular  damage  and  insufficiency,  concentric  arteriosclerosis  of  graft  vessels  and 
parenchymal  fibrosis  and atrophy.   Chronic  rejection may be due to antigen-specific 
alloreactivity and antibody deposition, but may also be due to non-specific late effects of 
ischemia-reperfusion  injury,  long-term  side-effects  of  cytotoxic  drugs  such  as 
cyclosporine and even infection with cytomegalovirus.  It has also been shown that the 
indirect pathway of allorecognition is involved with the pathogenesis of chronic rejection 
Figure 1.  Schematic depicting 
methods of allorecognition in 
transplant rejection.  Direct 
Presentation: Post 
transplantation, dendritic cells 
(DCs) from the donor leave the 
graft and circulate via 
lymphatics to regional lymph 
nodes and via blood vessels to 
the spleen.  DCs present 
peptides from the donor on 
their own major 
histocompatibility complex 
(MHC) to the T-cells of the 
recipient, binding to the host T-
cell receptor (TCR). Direct 
presentation brings about an 
alloreactive T-cell population 
that recognizes and kills the 
graft.  Indirect Presentation: 
Post transplantation, host DCs 
migrate into the graft, and take 
up and process proteins from 
recipient cells. These host 
DC's migrate back to lymph 
nodes and spleen and present 
foreign peptides on self MHC, 
leading to an allo-specific 
response (15).
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as well (17). Unfortunately, chronic rejection is generally not amenable to treatment, and 
is the major cause of late graft dysfunction, occurring many years post-transplant.   It is 
due to chronic rejection that despite improvements in short-term graft survival, long-term 
survival has seen little improvement, with a renal transplant half-life survival remaining at 
roughly 8 years (18), (5).
Medical Treatment of Rejection
Current  medical  management  of  transplant  is  aimed  at  modulation  of  acute 
rejection.  Acute rejection is usually treated with short bursts of high-dose steroids which 
is often sufficient  to prevent  the rejection from progressing.   Maintenance therapy is 
given  to  most  patients  which  consists  of  chronic  immunosuppression  using  multiple 
drugs in combination; often as “triple therapy”.  Triple therapy includes a steroid with the 
addition  of  a  calcineurin  inhibitor  such  as  cyclosporine  or  tacrolimus  and  an 
antiproliferative agent such as mycophenolate mofetil.  Maintenance therapy serves to 
not only treat acute flares of rejection, but to prevent them from initially occurring.  In 
some patients in which calcineurin inhibitors and steroids are contra-indicated, mTOR 
(mammalian target of rapamycin) inhibitors such as sirolimus may be substituted.  In 
high risk patients, antibody treatments may be added as well to augment the response. 
The section below will briefly describe the types of medications currently available.
Corticosteroids: These medications are derivatives of the glucocorticoid family of 
steroids.  The most commonly used is prednisone which is a synthetic analog of cortisol, 
and all  drugs in  this  class share similarities in  structure and function.   They act  via 
intracellular receptors that regulate transcription of specific genes.  Up to 1% of genes 
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can be regulated by glucocorticoids, which cause a complex set of physiological effects. 
Their role in immune modulation lies in their ability to do the following:  decrease IL-1, IL-
3, IL-4, IL-5, IL-8, TNF-alpha and GM-CSF causing reduced inflammatory response, and 
reduced  activation  of  the  immune  system.   Decreased  phospholipase  A2  and 
cyclooxygenase also serve to decrease prostaglandins and leukotrienes (13).  Steroids 
decrease  adhesion  molecules  causing  reduced  emigration  of  WBC's  out  of  blood 
vessels and increase the production of endonucleases causing increased apoptosis in 
lymphocytes.  The negative side effects however are numerous, especially with long-
term use.   These  include  weight  gain,  diabetes,  hypertension,  fluid  gain,  electrolyte 
abnormalities,  bone loss  and skin  thinning  (19).   The benefits  therefore need to  be 
carefully balanced against the side effects with long-term use.  
Calcineurin  Inhibitors: These medications block  the calcium activated enzyme 
calcineurin, which is essential for the production of IL-2.  T cell growth is mediated in 
large part  by activation  with  IL-2,   so calcineurin  inhibitors  serve to decrease T cell 
proliferation.   They  work  very  effectively  to  decrease  the  T  cell  response  in  acute 
rejection.  These inhibitors also decrease IL-3, IL-4, GM-CSF and TNF-alpha, and inhibit 
B-cell proliferation (13).  Cyclosporine and tacrolimus are the two drugs in this class that 
are  commonly  used  in  clinical  transplant.   Despite  their  more  specific  effects  as 
compared to steroids, they can be very toxic as well especially to the kidneys and other 
organs.  Tacrolimus is considered more powerful than cyclosporine and has a slightly 
better side-effect profile and is now used more frequently (20).
mTOR inhibitors: Instead of blocking the release of IL-2 as calcineurin inhibitors 
do, these medications bind to the mTOR complex thereby inhibiting the response to IL-2 
and blocking proliferation of T and B cells.  Sirolimus (also known as rapamycin) is the 
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major  drug  in  this  class.   It  is  considered  less  toxic  than  the  calcineurin  inhibitors 
especially  to  the  kidneys,  and  is  generally  well  tolerated  despite  profibrotic  and 
prodiabetogenic effects(20).  
Antibody Treatments:  These drugs are the latest in targeted therapies, and can 
specifically interfere with immune responses with less toxicity.  Older versions like anti-
lymphocyte  globulin  have been used for  years  as  a  non-specific  treatment  that  can 
remove  unwanted  lymphocytes  (they  lack  specificity  however,  and  remove  non-
allospecific  lymphocytes as well),  but  their  use has been limited by side effects like 
serum sickness which is due to antigenicity after production in horses.  However, more 
specific antibody treatments have developed as well.  OKT3 is no longer commonly used 
due to a serious cytokine release syndrome and long term lymphoproliferative disorders, 
but was effective at specifically binding to T cells in the modulation of acute rejection. 
More recently, drugs like daclizumab have been created, employing a similar strategy to 
mTOR and calcineurin inhibitors by blocking IL-2, but instead via direct binding to its 
alpha  subunit.   The  main  advantage  of  these  appears  to  be  their  reduction  in 
opportunistic infection risk. (20) (13)
Antiproliferatives:   These  drugs  are  widely  used  in  transplant  and  include 
mycophenolic acid,  azathioprine and cyclophosphamide.   They inhibit  DNA synthesis 
and  exert  the  majority  of  their  pharmacologic  action  on  rapidly  dividing  tissues. 
Azathioprine is converted within the body into a purine antagonist that competes with 
inosine  monophosphatase  inhibiting  the  synthesis  of  purines  and  decreasing  DNA 
synthesis (13).  Cyclophosphamide is an alkylating agent that directly incorporates itself 
into DNA .  Both have numerous toxicities and side effects, with cyclophosphamide side-
effects including hemorrhagic cystitis and bladder cancer (13).  
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Mycophenolic acid (MPA) has helped to dramatically decrease the incidence of 
acute rejection when used in combination with other medications.  It has been approved 
for use in the prevention of acute rejection in renal, liver and heart allografts, and will 
likely soon be approved for use in pancreas and lung transplants as well (21).  It is now 
being considered an excellent alternative to the older azathioprine, with better treatment 
of  acute  rejection.   MPA blocks  inosine-5'-monophosphate  dehydrogenase  (IMPDH), 
inhibiting the creation of guanosine.  Lymphocytes lack the salvage pathway for creation 
of purines and are therefore stalled in their replication, with subsequent decreases in T 
cell proliferation and decreases in Ig production by B-cells (21).  Furthermore, MPA has 
been shown to cause apoptosis in T cells (22), and affect other aspects of the immune 
system and inflammation as well.  MPA has been shown to decrease the dendritic cell 
response,  decrease maturation  and  prevent  antigen  presentation.   It  also  has  been 
shown to reduce monocyte proliferation and recruitment into sites of inflammation (21), 
and to decrease general inflammation through its actions on macrophages, decreasing 
nitric oxide and superoxide formation.  MPA has also been shown to decrease arterial 
smooth muscle proliferation which can contribute to graft arteriopathy and rejection (22). 
It  is used clinically in its pro-drug formulation as mycophenolate mofetil  (MMF) which 
which  is  converted  into  MPA in  the  liver  and  was  designed  for  use  because  of  its 
superior  bio-absorption.   MPA has  minimal  side-effects  compared  with  many  other 
immunosuppressives  which  has  made  it  an  attractive  medication.   The  side-effects 
however include infection risk, GI toxicities, thrombosis and rare severe complications 
(20).
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Overview of Nanosystems
Nanotechnology was first discussed in 1974 by Norio Taniguchi in his paper “On 
the Basic Concept of Nano-technology”.  He defined the technology based upon small 
particles in the nanometer range in size that behave as an individual unit in terms of their 
chemical  and physical  properties  (23).   As material  technology has advanced,  these 
particles  have  been  created  from  numerous  substances  including  metals,  plastics, 
organic molecules, inorganic molecules like silica and a multitude of other substances. 
Due to this variability in design, the individual properties and functions of nanoparticles 
can  be  enormously  different.   Nanomedicine  gained  interest  as  an  off-shoot  of  this 
technology for use in both diagnostic imaging as well as drug delivery, and over the past 
two decades there has been an explosion in research and development (24), (25), (26).  
In particular, there has been considerable focus on using nanoparticles for drug 
delivery.   Nanoparticles  serve  as  an  optimal  drug  delivery  vector  for  a  number  of 
reasons.  The creator has structural control over the size and shape of the drug cargo-
space and the particles can serve as a precise scaffold or  container  with  high drug 
carrying capacity; important in having plasticity in drug delivery.  They can be made to be 
biocompatible with nontoxic polymers, allowing for non-immunogenic, non-toxic delivery 
within the body.  They can have well-defined modifiable functionality for targeting with 
antibodies and ligands specific  to  any tissue or  cell  type within the body leading to 
decreased doses to tissues that may be sensitive to the drug, and increased doses to 
the tissues of interest.  The nanoparticles can be created to undergo cellular adhesion, 
with subsequent endocytosis, and trafficking to allow delivery of drugs into the cytoplasm 
or  nucleus.   They  can  have  well  controlled  and  reproducible  bioelimination  or 
biodegradation,  which  is  extremely  important  in  understanding  how  to  reproducibly 
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deliver drug for treatment.  The nanoparticles can be developed to have controlled or 
triggerable  drug  release.   Nanoparticles  isolate  and  protect  the  encapsulated  drug 
against inactivation during transit through the body to target cells.  They can be designed 
with  minimal  nonspecific  cellular  and  blood-protein  binding  properties  in  order  to 
decrease non-specific uptake, decrease systemic doses and increase local doses.  The 
nanoparticles  can  be  created  for  easy  and  consistent  reproducibility  and  synthesis. 
They can improve solubilization of  the drug that  may be non-soluble.   They can be 
created for  introduction  via  noninvasive  routes.   Ultimately  these particles  can have 
improved bioavailability and release profiles with reduction in administered drug doses, 
improving safety and diminishing side effects.  Lastly, nanoparticles are an optimal drug 
delivery mechanism because they can be used as sustained release vectors, possibly 
improving compliance, quality of life and outcomes.  Successful nanosystems also have 
the potential to evolve as we discover new proteins, receptors and ligands involved in 
diseases, offering opportunities to achieve drug targeting with newly discovered disease-
specific targets (7).
Liposomal Particles
Liposomal  particles  are  currently  in  use  commercially  for  drug  delivery  of 
chemotherapeutics  and  antibiotics,  and  have  long  been  studied  for  improving  drug 
toxicities and delivery characteristics.  These nanoparticles are composed of amphiphilic 
phospholipids that form bilayers with encapsulation of an aqueous interior.  These small 
(80 to 100 nm) particles can be loaded with hydrophobic substances within the bilayer or 
hydrophilic substances within the aqueous core.  Loading of drugs is achieved through a 
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variety  of  techniques   that  allow  for  encapsulation  of  drugs  such  as  vincristine, 
doxirubicin and amphotericin  (27) (28).  The first generation of liposomal particles had 
the trouble of being rapidly cleared by the body due to rapid opsonization and uptake by 
the mononuclear phagocytic system.  This issue was addressed with the use of poly-
ethylene glycol (PEG)  (8) coating which “hides” the particles from immune uptake and 
enhances  distribution  and  bioavailablitity  (29).   PEGylated  particles  were  found  to 
localize  in  tissues  with  newly  formed vasculature  and in  this  localization  a  “passive 
targeting”  (30) was found which underlies the utility in liposomal anti-cancer therapies 
causing relative increases in drug concentration within the leaky vasculature of tumors 
as compared with the normal vasculature of healthy tissues  (31) (24).   Furthermore, 
liposomal particles have the potential to be targeted via addition of antibodies onto their 
surfaces.   There  is  much  ongoing  research  looking  at  the  utility  of  targeting  drug 
encapsulated liposomal  nanoparticles.   However,  liposomal  systems in  general  have 
some disadvantages in  terms of  drug delivery.   There is  generally poor control  over 
release of the encapsulated drug into the blood, causing unintended leak.  There are 
also questions about  the efficiency of  encapsulation and the stability of  the particles 
during longer storage(32)(33).
Dendrimer Particles
Dendrimer  particles  are  polymerized  branching  structures  emanating  from  a 
central  core  that  roughly  form  a  sphere  in  shape  (34).   The  branching  creates  a 
labyrinthine core that can be utilized for entrapment of small substances.  Furthermore, 
the terminal ends of the branches can be utilized and made functional via binding with 
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ligand, antibodies, and imaging enhancing molecules.  Our collaborators, Dr Fahmy and 
his  lab  have  used  these  particles  extensively,  where  they  have  utilized  a 
polyamidoamine (PAMAM) dendrimer with PEG attached to the core for targeting T cell 
populations  by  coupling  streptavidin  to  the  terminal  chain  and  using  biotinylated 
antibodies against CD3 and peptide/MHC complexes.  With doxirubicin bound to the 
Figure 2.  A schematic created by our collaborators in the laboratory of Dr Fahmy.  These represent the 
three more commonly used types of nanoparticles in medical practice.  A.  Liposomal systems are 
widely used in medicine with encapsulation of drugs such as doxirubicin and amphotericin.  These 
particles consist of a lipid bilayer and an aqueous core.  Hydrophobic drug can be carried within the 
phospholipd bilayer and hydrophilic drug can be carried in the core.  B.  These are solid 
biodegradeable polymer based nanoparticles such as those made with poly-lactic and glycolic acid 
(PLGA).  These are flexible systems that allow for surface bound antibody targeting, central drug 
carrying and a controlled half-life.  C.  Dendrimer particles are finely branched structures with a central 
core.  The branching creates a labrynth core for drug delivery and the ends of the branches can be 
functionalized with antibody for specific targeting.
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particles, their  lab found excellent inhibition of polyclonal and antigen-specific T cells 
(32).  
Solid Biodegradable Particles
Polymerized  particles  appear  to  have  many  advantages  including 
biocompatability, biodegradability and functionalization with loading and targeting  (35). 
Encapsulation  using  polymerized  nanoparticles  gives  the  operator  specific  and 
reproducible control  of  the biodegradability and release of  the internalized drug  (35). 
There  are  currently  numerous  materials  used  in  the  formulation  of  these  types  of 
nanoparticles, but particles made from polymers of lactic and glycolic acid (PLGA) will be 
focused on in more detail.  These particles combine a hydrophobic poly-lactic acid (PLA) 
polymer with a hydrophilic  poly-glycolic acid (PGA) polymer.  These are desirable to 
utilize in a drug delivery system due to the fine control of the drug delivery that can be 
obtained by changing the relative ratios of each substance within the nanoparticle.  PLA 
has a half-life of months and PGA of days, thereby giving the operator a range of options 
in  terms  of  drug  release  by  changing  the  PLA:PGA  ratio  (36).   Drugs  can  be 
encapsulated and attached in a variety of ways including hydrophobic entrapment and 
direct  conjugation  to  the  PLGA surface,  allowing  a  wide  variety  of  substance  to  be 
brought together in one functionalized nanoparticle unit (37).  Furthermore, this material 
has been shown to be safe in humans in thirty years of use (38) (39).  The breakdown 
products of these particles, lactic and glycolic acid are physiologically normal substances 
involved in the Krebb cycle and are broken down into carbon dioxide and water without 
affecting normal cellular functions (40).
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Micro-sized  PLGA particles  encapsulated  with  chemotherapeutic  drugs  have 
been  shown  to  have  improved  drug  efficacy  compared  with  free  drug  (41).   PLGA 
nanoparticles loaded with doxirubicin was shown to have prolonged release profile over 
a month and a similar effectiveness with in vivo injections in mice (42).  Not only have 
PLGA particles been shown to improve drug delivery, but they have even been found in 
one paper to increase drug efficacy in cancer cell lines reversing multi-drug resistance 
(43).  Currently, PLGA particles are found in clinical use as a depot form of GnRH called 
Lupron® (44).
Our collaborators in Dr Fahmy's lab have developed the ability to create nano-
sized  PLGA  particles  (Figure  3,  4),  with  encapsulation  of  both  doxirubicin  and 
mycophenolic acid, and direct conjugation of streptavidin onto the PLGA surface.  With 
the addition of streptavidin, they have created a system that can attach any biotinylated 
antibody to the surface of the particle, theoretically allowing for targeting any moiety of 
interest  that  has a commercially manufactured biotinylated antibody  (45) (32).   They 
have also added PEG to the surface to improve circulation of the particles.  Previously 
these particles were too difficult to manufacture and attach PEG.  PEGylation has been 
shown to be very important in nanoparticle drug delivery by increasing transit times and 
decreasing non-specific uptake and binding throughout the body.  The development of 
PEGylated solid  biodegradable  nanoparticles  has  lagged behind the  development  of 
liposomal  PEGylated  particles  due  to  the  technical  difficulties  in  attachment  to  the 
surface and creation of functionalized particles (35).  Our collaborators have successfully 
developed  a  technique  that  reliably  and  reproducibly  functionalizes  PLGA particle 
surfaces  (Figure 3).   They recently published a  paper  using PLGA encapsulation of 
doxirubicin where they were able to improve on the cytotoxicity while decreasing the 
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non-specific cardiotoxicity (35).
Dr Fahmy's lab has also been looking at targeting T cells for both imaging and 
drug  delivery  using  these  particles  and  antibodies  against  CD3  (46).   Their  lab 
suggested that due to their small size, the PLGA particles would be internalized into the 
T cells  and  would  act  as  an  intracellular  drug reservoir  allowing  for  sustained local 
release affecting only the cell population of interest.  In their work they found the CD3 
targeted particles encapsulated with doxirubicin were able to decrease proliferation of T 
cells  after  CD3  stimulation  showing  successful  targeting  and  delivery  of  drug  (32). 
These particles are also gaining attention by our collaborators as potential vehicles for 
vaccine delivery.  The nanoparticles containing the viral proteins are internalized by both 
dendritic cells (DCs) and T cells which then become activated to prime a potent adaptive 
immune response (47)(48).
Figure 3.  Electron Microscopy 
of [lactide-co-glycolide] (PLGA) 
particles.  Particles w ere 
created in the lab of  our 
collaborator Dr Fahmy.  
Production of  PLGA 
nanoparticles results in small 
particles w ith an average size 
of  130nm.  These particles can 
be encapsulated w ith a variety 
of  substances including 
f luorescent imaging molecules 
such as rodamine and 
coumarin-6, drugs such as 
mycophelonic acid (MPA) and 
doxirubicin, and magnetic 
resonance enhancers such as 
gadalinium.  The surface of the 
particles is used for 
attachment of  avidin, and this 
can be utilized for the 
attachment of  biotinylated 
antibodies.
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Nanomedicine in Transplantation
The majority of research into nanoparticle drug delivery has examined uses in 
cancer treatment and diagnosis.  The literature on nanoparticles in transplant rejection is 
far more limited.  Very few studies were found in an extensive literature search on the 
use of nanoparticles in modulation of transplantation.  One group has looked at PLA 
nanoparticles stabilized with cholesterol-modified chitosan encapsulated with rapamycin 
in  a  corneal  transplantation  rabbit  model.   This  group  found  that  the  nanoparticles 
exhibited excellent  retention in  the precorneal  area allowing for  sustained release of 
rapamycin.  When compared to topical free rapamycin they found significant efficacy in 
the treatment with similar (but slightly improved) mean survival times of the grafts (49). 
Two  other  groups  looked  at  cyclosporine  formulated  into  PLGA particles  for  use  in 
corneal transplants.  Both sets of researchers found significant increases in mean graft 
survival times in animals receiving the nanoparticles loaded with cyclosporine(50)(51)
(52).   Using  PLGA encapsulated  with  tacrolimus,  another  group  has  also  looked  at 
corneal transplant rejection.  Similarly to the groups using other immunosuppressives, 
PLGA loaded with tacrolimus delayed graft rejection and improved mean survival times 
(53). 
Using  liposomal  encapsulations  of  tacrolimus  and  rapamycin,  one  group  of 
researchers have published a number of manuscripts looking at modulation of transplant 
rejection in dopaminergic grafts in a Parkinson disease mouse model.  These papers 
found  decreased  immunorejection  of  grafts  in  groups  receiving  treatment  with 
liposomally encapsulated drug  (54)(55)(56).  Another group has been using liposomal 
preparations of tacrolimus in an islet cell transplantation model.  They found significantly 
delayed graft rejection after using the liposomal formulation (57).  This same Canadian 
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group  also  published  a  brief  report  indicating  the  improved  side-effect  profile  and 
delayed skin and heart transplant rejection using oral liposomal tacrolimus (58).  There 
have not been any skin or solid organ transplant models that utilize PLGA particles.
There  is  also  a  small  body of  research relevant  for  transplant  that  does  not 
directly  use  a  transplant  model.   One study of  interest  looked at  nanoparticles  and 
immune modulation, examining the role of PLGA particles loaded with rapamycin and 
their activity against dendritic cells.  Interestingly as compared with free rapamycin which 
has little affect on dendritic cells, PLGA loaded drug caused a decrease in maturation 
markers such as MHC II,  CD86 and CD40.  In addition,  PLGA delivered rapamycin 
decreased  cytokine  production  and  decreased  T  cell  proliferation  using  mixed 
lymphocyte  reactions  (59).   This  same  group  has  also  used  PLGA encapsulated 
rapamycin particles and looked at  the expression of  ICAM-1,  an important  adhesion 
molecule that facilitates the interaction of T cells with dendritic cells.  They found that 
PLGA particles but not free-drug were able to down-regulate the expression of ICAM-1. 
Furthermore they found an immunosuppressive array of cytokine production with the 
rapamycin loaded PLGA particles (60).
Most other work in nanoparticles that is relevant to transplantation involve studies 
examining the encapsulation of immunosuppressive medications, but these studies do 
not directly look at their application in post-transplant treatment.  One group successfully 
used PLGA encapsulated rapamycin (sirolimus)  in  a vascular  re-stenosis  model  and 
were able to increase anti-proliferation with PLGA loaded drug as compared to free drug 
(61).   Another  group  has  looked  at  the  use  of  oral  PLGA particles  loaded  with 
cyclosporine.  This study looked at pharmacokinetics and also found decreased renal 
toxicity in the oral nanoparticle drug vector as compared with the standard drug delivery 
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(40).   
 
Research Question and Design
Our  study  examined  the  use  of  PLGA  nanoparticles  encapsulated  with 
mycophenolic acid for the modulation of transplant rejection in a murine skin transplant 
model.  We chose to use PLGA particles as these are considered by many (including our 
collaborators)  to  be  the  best  system for  sustained  release,  specific  targeting,  future 
clinical  utility  and  can  now  be  manufactured  by  our  collaborators  using  what  they 
consider a superior technique with the addition of PEGylation  (35).  We chose to use 
mycophenolic acid as our immune modulator as it is commonly used clinically and our 
collaborators have had success with its encapsulation within the PLGA particles.  They 
have previously been working on using PLGA encapsulated with MPA in a lupus mouse 
model with preliminary results that have looked excellent (unpublished data).  We chose 
to do skin transplants in mice as this is a commonly used model for transplantation that 
has relative  technical  ease.   The skin transplants  are highly immunogenic  and their 
resistance  to  modulation  makes  them  an  excellent  candidate  for  testing  immune 
modulating treatments  (16, 62).  Furthermore, our lab has had great experience using 
this model in the past (63).  As such, we looked at the use of MPA loaded particles, both 
targeted to CD4+ T cells and non-targeted, and compared the use of these particles to 
empty  particles,  free  doses  of  MPA and  non-treatment  groups.   We examined  skin 
transplants in a major MHC mismatch BALB/C to C57BL/6 model as an initial test of 
MPA loaded particles to effect a response.  We also wanted to test the ability to target 
specific cell populations using the targeted MPA particles.  To accomplish this we used a 
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CD4-dependent  transplant  rejection  model,  using  a  less  immunogenic  single  MHCII 
mismatch model with B6.H-2bm12 (spontaneous mutation of I-Ab region causing prompt 
rejection) to C57BL/6 mice.  Our hypothesis was that specific targeted drug delivery via 
nanoparticles would increase graft acceptance and increase the mean survival times of 
transplanted skin in both our high and low immunogenic models.  Our secondary aims 
were to analyze the role of cytokine signaling between treatment groups, analyze the 
expression of surface markers using flow cytometry and assess T cell proliferation with 
different treatment groups using mixed lymphocyte reactions.  When our results showed 
that  non-targeted  nanoparticles  also  improved  graft  acceptance,  we  examined  the 
impact  of  nanoparticle  therapy  on  dendritic  cells,  particularly  how  particles  impact 
costimulatory and coinhibitory pathways that DCs use to modulate T cell responses in 
rejection.
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Experimental Methods
Animals
All animals used were housed in the Anlyan Center Animal Facility,  and used 
according  to  Yale  University  IACUC protocol.   BALB/C (H-2d),  C57BL/6  (H-2b)  and 
B6.H-2bm12 (H-2bm12) mice were purchased from the National Cancer Institute for our 
experiments and CD4 knockout mice from Jackson Labs.  B6.H-2bm12 mice are a strain 
with a spontaneous mutation of the I-Ab molecule resulting in a 3-aa substitution in the 
hypervariable region of the Aβ chain.  They are otherwise identical to C57BL/6 mice.  All 
animals were housed under pathogen-free conditions, and animals were not used if they 
had any skin lesions or other signs of sickness.  
Nanoparticles
All  nanoparticles were created in  the lab of  Tarek Fahmy,  by our collaborator 
Michael  Look,  a  PhD  candidate  in  Bioengineering.   Nanoparticles  were  made  of 
polymers of lactic and glycolic acid, with avidin impregnated into the surface.  20 mg of 
dry MPA was added in 400 uL of methanol (50 mg/mL stock) and subsequently added to 
2 ml ethyl acetate containing 200 mg polymer and the methanol was evaporated off. 
Dropwise, 2mL of organic phase of MPA/PLGA/ethyl acetate was added to 4 mL of a 
3.75% PVA solution containing 5 mg palmitate-avidin under vortex.  The solution was 
sonicated  under  ice  at  38%  amplitude,  3X  for  10  seconds  to  form  an  emulsion. 
Nanoparticles were added to a beaker of 100 mL of 0.3% PVA and stirred in the dark for 
3 hours at room temperature.  After 3 hours of incubation, particles were collected into 
Kassis, Elias                                                                                                           Page 28
centrifuge  tubes  and  spun  at  12000  rpm for  12  minutes  at  4ºC.   Supernatant  was 
dumped and particles thoroughly resuspended in ~40-50 mL d.i. water using a sonicator. 
Particles were spun and washed once.  Particles were collected in a single 50 mL falcon 
tube in ~5-10 mL d.i. water.  Particles were passed through a 40 um filter to remove 
aggregates (and PVA debris), and frozen at -80°C for at least 1 hour.  Particles were 
lyophilized for 48 hours in the dark.  The nanoparticle yield from this protocol had a 
theoretical  maximum  avidin  coverage  of  25  ug  avidin-palmitate  per  mg  of  polymer. 
Coumarin-6,  and rhodamine particles  were  created similarly  but  with  loading  of  dye 
instead of drug (Figure 4) for fluorescent imaging.
In  preparation  for  injection  into  mice  for  treatment  of  transplant  rejection, 
nanoparticles  were  prepared  for  targeting  or  non-targeted  groups.   All  nanoparticle 
preparation  prior  to  injection  was  done  by  either  Dr.  Anushree  Shirali,  (nephrology 
fellow), or Elias Kassis.  In the targeted groups biotinylated RM4-4, a monoclonal non-
depleting  antibody  binding  CD4  was  attached  to  the  streptavidin  moieties  of  the 
nanoparticles.   Nanoparticles  were  weighed,  suspended  in  PBS and  incubated  with 
RM4-4 antibody at a concentration of 7.5ul (0.5mg/ml) biotin per 1mg particle.   PEG 
was added at 1:1 molar ration(M.W. 10000) at 0.75 ul (5mg/ml).  After 30 minutes at 
room temperature, particles were spun down, the supernatant removed and the particles 
re-suspended  in  PBS  to  obtain  an  injection  dose  of  20mg/ml  (250  ml  injection: 
5mg/animal).   The non-targeted particles were incubated with PEG alone.  MPA-loaded, 
empty, coumarin-6 and rhodamine particles were prepared identically for drug delivery 
and fluorescent imaging.
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MPA Release From Particles
This experiment was done by Michael Look in the lab of Dr Tarek Fahmy.  1-10 
mg/ml of MPA-loaded particles were prepared in PBS.  The particles were place in a 
microcentrifuge tube and placed on a shaker at 37ºC.  Once per day the tubes were 
spun at 13200 rcf for 10 minutes.  The supernatant was collected and stored at -20ºC 
until ready for use.  The pellet was resuspended in 1ml PBS and allowed to incubate for 
24  hours  until  the  next  supernatant  collection.   This  continued  for  one  week.   The 
supernatants  were  analyzed  for  MPA on  a  SpectraMax  M5  plate  reader  (Molecular 
Devices) with excitation 340nm and emission 450nm with these data points plotted to 
MPA
MPA
Figure 4.  Figure 
taken from our 
collaborators (35), 
showing a schematic 
of PLGA nanoparticle 
creation. A) Synthesis 
of avidin-lipid 
conjugate. Avidin is 
reacted with palmitic 
acid–NHS in a 2% 
deoxycholate buffer to 
form avidin-palmitate 
conjugate. (B) The 
conjugate is then 
added during the 
aqueous phase of a 
modified single-
emulsion technique to 
form avidin-coated 
PLGA nanoparticles 
(C) Avidin-coated 
nanoparticles can then 
be incubated in 
solution with 
biotinylated ligands to 
form surface-modified 
nanoparticles.
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determine MPA release.
 
Transplantation
All  transplantation  was  performed  by  either  Elias  Kassis  (BALB/C)  or  Dr 
Anushree Shirali (B6.H-2bm12 mice).  On the day of transplantation, donor mice were 
shaved, cleaned with alcohol and iodine and sacrificed using isofluorane, and skin was 
removed.  Fascia was cleared from under the dermis and skin was placed in PBS on ice 
until ready for transplant.  Recipient mice were anesthetized with isofluorane shaved, 
cleaned with alcohol and betadine.   With fine scalpels a 2x2 cm square area of skin was 
removed from the right dorsal thorax.  The donor skin was cut to size and attached to the 
host using skin staples.  Bacitracin was placed topically and a bandage put in place. 
The bandages were removed at 1 week post-operatively.  Mice were given carprofen in 
their water for analgesia as per standard protocol.
At day 0, day 4, day 7, day 14 and 21, animals were injected with their treatments 
(Figure 5).  Treatment groups were; Group 1: Control, PBS treatment.  Group 2: Non-
targeted  empty  particles  at  5mg  per  animal  per  treatment  time.  Group  3:  free 
mycophenolic acid at 5mg total dose injection per animal per treatment time (initially 
intermittently at day 0, 4, 7, 14, 21.  In a separate group [n=3] free MPA was given daily). 
Group  4:  Non-targeted  nanoparticles  loaded  with  mycophenolic  acid  at  1-10ug/mg 
particles, given in total injections of 5mg particles per animal per treatment time.  Group 
5: CD-4 targeted (RM4-4 antibody) nanoparticles loaded with mycophenolic acid at 1-
10ug/mg particles, given in total injections of 5mg particles per animal per treatment time 
(Figure 5).  Injections were done intraperitoneally.  Animals were followed for rejection 
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with complete rejection the primary end point.  Complete rejection was considered to be 
>70% scabbing over  of  the graft,  or  shedding of  the graft.   In  transplanted animals 
treated with GK1.5, animals were given 150 ug intraperitoneal injections at five times 
points (day 0, 2, 10, 14, 21).   Transplants done with CD4 knockout animals were done 
identically as the other transplanted animals but no treatment was given and animals 
were followed for rejection.
Dendritic Cell Collection
Dendritic cells were collected and grown by both Elias Kassis and Dr. Anushree 
Shirali.  Dendritic cells were harvested from post-treatment mice (transplant mice after 
Host Mice
C57BL/6
Donor Mice
BALB/c
Donor Mice
B6.H-2bm12or
Control: PBS
Empty Nanoparticle 
(5mg/injection)
Free MPA, daily or 
intermittent 
(5mg/injection)
Non-targeted, MPA-
loaded nanoparticle 
(5mg/injection)
CD4-targeted, MPA-
loaded nanoparticle 
(5mg/injection)
Treatments
(Day 0, 4, 7, 14, 21
Or daily MPA)1.
2.
3.
4.
5.
Figure 5.  Study design for transplantation.  BALB/c or B6.H-2bm12 mice are used to harvest 
donor skin and C57BL/6 mice are used for the host.  Host mice are treated on day 0, 4, 7, 14, 21 
with treatment groups.  After skin transplantation, mice are measured for graft survival, used to 
examine ex vivo proliferation of T-cells via mixed lymphocyte reaction, dendritic cells collected 
from draining lymph nodes and measured for maturation markers, numbers of regulatory T-cells 
examined in peripheral blood, and graft infiltration determined by immunohistochemistry after 
biopsy of the graft.
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complete  rejection,  or  at  specific  time  points),  as  well  as  naive  mice  that  had  not 
received a skin transplant.  Long bones of the mice were crushed using a mortar and 
pestle  and  bone  marrow was  filtered from tissue  and  bone  while  rinsing  with  PBS. 
RBC's were lysed using a hypotonic ammonium chloride buffer.  Mixed bone marrow 
cells  were  purified  for  dendritic  cells  using  complement  binding  and  killing  with 
antibodies  against  GK1.5,  B220,  GK2.43,  TIB211,  TIB120  and  rabbit  complement 
incubated for  one hour  (Gift  from the lab  of  Dr  Ira  Mellman).   After  purification  and 
counting using a hemocytometer with 64x64 grid, dendritic cells were plated in 24 well 
plates at 1million cells/well and allowed to grow for 3-5 days in the presence of 1% GM-
CSF in RPMI media at 37º C in a 5% CO2 incubator.  
Dendritic cells used for MLR or cytokine analysis.  On day 3 or 5 post-incubation, 
wells of dendritic cells were treated with MPA-nanoparticles at 1mg/ml, 0.1mg/ml and 
0.01mg/ml.  Empty nanoparticles were given at the same dosing.  Free MPA was given 
at doses of 5-10ug/ml, 0.5-1.0ug/ml,  0.05-0.1ug/ml and 0.005-0.01ug/ml.  The range in 
dose was due to different batches of nanoparticles and slight difference in loading of 
MPA in each batch.  The free MPA was given to roughly match the total amount of MPA 
per MPA-loaded nanoparticle dose.  On day 5 or 6, some dendritic cells were stimulated 
with  LPS  (25-50ng/ml)  as  a  maturation  stimulus,  and  allowed  to  incubate  for  and 
additional 24 hours before use.
Splenocyte and CD4 Collection
Spleens were collected from mice, homogenized, and filtered through a mesh 
screen by either Elias Kassis or Dr Anushree Shirali.  RBC's were destroyed using RBC 
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lysis buffer (hypotonic ammonium chloride buffer) and cells were either set aside for use 
or enriched for CD4 cells.  CD4+ cells were enriched via negative selection using a kit 
from EasySep  according to the manufactures instructions (Stecell Vancouver, Canada) 
that  negatively selected for  CD4 cells  using magnetic  particles and removing CD8+, 
CD11b+, CD19+, CD45r+,  CD49b+, Ter119+ cells.   Enriched CD4 T cells  were then 
used for MLR.
Mixed Lymphocyte Reactions
Mixed Lymphocyte Reactions (MLR's) were undertaken using purified dendritic 
cells or  splenocytes from the donor BALB/C or B6.H-2bm12 mice cultured with CD4 
enriched splenocytes from C57BL/6 host mice and were done by Elias Kassis and Dr 
Anushree Shirali.  In the initial BALB/C to C57BL/6 ex vivo experiment, mixed BALB/C 
splenocytes (at 1x106 cells/well) were incubated with C57BL/6 CD4 cells that had been 
isolated and pooled from mice on day 35 post-transplant (at 1 x 105 cells/well).  Cells 
were plated at 1:10 ratio (CD4:DCs) per well and allowed to co-incubate for 48-72hours. 
In the  in vitro studies, dendritic cells were incubated with nanoparticles encapsulated 
with  MPA  (at  1mg/ml,  0.1mg/ml,  0.01mg/ml  and  0.001mg/ml  depending  on  the 
experiment),  empty nanoparticles (at the same doses as loaded particles), free MPA (at 
8-10ug/ml, 0.8-1ug/ml, 0.08-0.1ug/ml and 0.008-0.01ug/ml), and no treatments and then 
stimulated with LPS (as described in the dendritic cell section) prior to coculture with the 
C57BL/6  CD4 cells.   In  all  experiments,  the  cells  were  co-cultured  in  Bruffs  media 
containing 10% FCS, 1% pen/strep, 50um 2ME and 2 mM L glutamine.   3H-thymidine 
was then added and the cells incubated for an additional 18-24 hours at 37º C in 5% 
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CO2 incubator.  Cell proliferation was measured using a Beta plate scintillation counter 
after  washing  and  extracting  3H-thymidine  from  the  proliferative  cells  using  a  cell 
harvester from Scatron Instruments.  
ELISA
ELISA analysis was done by either Elias Kassis or Dr Anushree Shirali.  Mixed 
lymphocyte  reactions  (as  described)  had  aliquots  of  the  supernatants  collected  for 
analysis.  DCs treated with MPA encapsulated nanoparticles, empty particles, free MPA 
and no treatment were stimulated with LPS (50ng/ml) and after 24 hours the cells were 
spun, and the supernatant collected for analysis.  96 well plates from Costar were used 
for culture.  ELISA kits from eBioscience were used.  Capture antibody (IL-2, IL-6, IL-10, 
IL-12,  TNF,  IFN)  was  attached  overnight  at  4ºC  at  1:250  dilution  in  ELISA buffer 
(eBioscience ELISA capture buffer).  Plates were washed 5x and were blocked for one 
hour at room temperature with ELISA assay diluent (eBioscience assay buffer provided 
at 5x solution).  After blocking supernatant samples were plated along with the standard 
curve dilutions.  The samples were incubated overnight at 4ºC and after washing were 
incubated with detection antibody at 1:250 dilution in ELISA assay diluent with avidin-
HRP   for  an  additional  30  minutes  and  finally  with  superaqua  blue  solution  (BD 
bioscience)until  full  development.   Standard  curves  were  created  in  duplicate  using 
standards for each antibody from E-bioscience.   The plates were read with a Synergy 
HT well reader at an absorbance of 450nm.
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Flow Cytometry
Flow cytometry was done by Elias Kassis and Dr. Anushree Shirali.  Cells were 
collected from transplant treatment groups in vivo by harvesting the spleen or draining 
lymph  nodes  of  transplanted  mice.   Cells  were  also  collected  from  in-vitro cell 
stimulations as described in early sections.  Fluorescent antibodies against CD4, CD3, 
CD11c,  CD25, CD40, CD80, CD86, MHCII,  B7-DC, B7-H1,  Thy1.2,  Annexin,  7-AAD, 
Foxp3 were purchased from eBioscience and BD Pharmingen.  These antibodies were 
incubated with the cells at their appropriate dilution for 30 minutes at 4º and spun twice 
to remove excess antibody with resuspension in PBS.  Cells that were not immediately 
analyzed were fixed in formalin-based fixative (BD cyotofix/cytoperm).  Cells stained with 
Foxp3 were permeabilized and fixed prior to incubation with antibodies as Foxp3 is an 
intracellular transcription factor.  The cells were analyzed using the FACS CALIBUR flow 
cytometry machines in the Yale Anlyan Center flow cytometry center.  Cells were gated 
on lymphocytes and dendritic cells using a side scatter and forward scatter setting that 
had been previously established by a member of our lab.  Single stained controls were 
used to set the gain and voltage in each channel and prevent overflow into neighboring 
channels  and  the  final  data  were  uploaded  and  analyzed  using  FlowJo  software 
(Treestar, Ashland, OR, USA).  
Histology, and Fluorescent Microscopy
Biopsies of the grafts were obtained at 15 days post-op from representative mice 
by Dr Anushree Shirali.  The biopsies were formalin fixed (10% formalin), and paraffin 
mounted on glass slides.  The tissues were H&E stained and then examined for cellular 
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infiltration, signs of inflammation and other tissue characteristics using a Leica DM IRB 
inverted microscope.
Dendritic cells were harvested and cultured for five days as previously described. 
On day 5, 1x106 cells were collected and plated on lab-tek chamber slides (Nunc) over-
night  for  attachment  by  Elias  Kassis  and  Dr  Anushree  Shirali.   Coumarin  6  loaded 
nanoparticles and empty nanoparticles were incubated with the plated dendritic cells. 
The slides were either incubated for 2 hours or 18 hours, then washed 3x with cold PBS. 
4% paraformaldehyde was used to fix the cells on ice for 15 minutes.  Cells were again 
washed were 3x with cold PBS, excess PBS was gently aspirated, and 2 drops of Anti-
Fade  Gold  w/DapI  was  added.   A  coverslip  was  placed  over  the  cells  prior  to 
examination under fluorescent microscopy using the green channel of the Leica DM IRB 
microscope.
Nanoparticle Biodistribution
To determine the biodistribution of targeted and non-targeted nanoparticles, Noah 
Capurso  an  MD  candidate  in  Dr  Tarek  Fahmy's  lab  used  rhodamine  encapsulated 
nanoparticles  with  either  PEG  alone  or  CD4/PEG  bound  to  the  particles  as  was 
previously  described in  the  nanoparticle  methodology.   Particles  were  injected retro-
orbitally  into one mouse/group/time point  of  harvest.   Targeted particle  animals were 
sacrificed at 1, 5 and 24 hours and non-targeted particles were harvested at 3, 8 and 24 
hours.  In our laboratory, Elias Kassis and Dr Anushree Shirali compared CD4-targeted 
and non-targeted coumarin-6 loaded particles with empty particles.  As a control, three 
naive  C57BL/6  mice  were  given  intraperitoneal  injections  of  empty  non-targeted 
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nanoparticles at a total dose of 5mg.  Non-targeted coumarin-6 loaded nanoparticles 
were injected into a second group of animals, and targeted coumarin-6 loaded particles 
injected into a third both at 5mg total dose as well.  After three hours, the mice were 
sacrificed.  Serum was collected by removal of blood via cardiac puncture, the blood 
allowed to clot, spun and serum removed from the remaining clot.  The liver, spleen, 
kidneys,  lungs  and  heart  were  all  removed,  weighed  and  homogenized  in  1  ml  of 
deionized water.  The tissues were frozen overnight at -80ºC and after thawing were 
mixed at 1:2 volume with 1% Triton X-100 in DMSO, incubated for 1hour at 37ºC to 
extract dye and Frozen again overnight at -80ºC.    Homogenate was spun the following 
day at max rpm for 10minutes and 200ul of the supernatant was transferred onto a black 
96well ELISA plate for fluorescent reading.  Standard curves were created using serial 
decreasing  concentrations  of  known  coumarin-6  concentrations  in  the  extraction 
solution.  Standards and samples were read using a fluorescent plate reader.  The total 
mass of coumarin-6/mass of tissue was calculated using the weights of the removed 
organs.  
Statistical Analysis
Comparison  of  means  was  performed using  two  tailed  T-tests,  and  repeated 
measures were compared using analysis of variance (ANOVA), with Bonferronis post-
test comparison of means.  Survival data between groups were compared using a Log-
Rank analysis.   All  results were evaluated using Graphpad Prism statistical  software 
(San Diego, CA, USA).  Statistical significance was considered by a p value of <0.05. 
Results are reported with mean values ± standard error.
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Results
Nanoparticle drug kinetics and distribution
With the design of clinically used medications, it is important to develop drugs 
that are predictable regarding their release and distribution.  To understand and evaluate 
the  drug  release  from  the  particles,  our  collaborators  looked  at  MPA-loaded 
nanoparticles in solution (at physiological pH and temperature designed to simulate  in 
vivo conditions) and measured the release of MPA within solution over the course of a 
week.   They showed the constant  release  profile  of  the  nanoparticles  with  a  linear 
release rate.  The release of MPA from the nanoparticles into the surrounding solution 
remained  steady  throughout  the  incubation  with  slow and  sustained  release  over  a 
seven day period (Figure 6).
To characterize  the  distribution  of  nanoparticles  within  our  murine  model  our 
collaborators did a biodistribution assay of rhodamine-loaded particles.  They looked at 
total fluorescence of each organ (1,5 and 24 hours for CD4 targeted and 3,8 and 24 
Figure 6. Controlled 
release graph of 
cumulative MPA 
release from 
nanoparticles loaded 
with 1 µg MPA/mg 
particle in phosphate 
buffered saline (PBS) 
buffer at 37 °C, pH 
7.4.  The assay 
shows that after an 
initial steep rate of 
release of 
encapsulate MPA, 
there is a constant 
rate of release. 
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hours  for  non-targeted)  after  retro-orbital  injection  of  CD4-targeted and non-targeted 
particles.   Fluorescence was converted to ng rhodamine per  gram of  organ using a 
standard  curve and  organ  weights,  and total  rhodamine  compared between groups. 
They found increased levels of rhodamine in the spleen (68 ng rhodamine/g organ) at 24 
hours, in the CD4 targeted group and only 4.8ng rhodamine/g organ in the non-targeted 
group, but only did the study in one animal per group (Figure 7).  Overall, the measured 
levels of nanoparticles were much higher in each organ in the CD4-targeted group, but 
only the 24 hour time point is directly comparable between groups for each organ due to 
the differences in other time points. 
We also looked at the biodistribution of the nanoparticles within the mouse after 
intraperitoneal  injection,  comparing  CD4  targeted-coumarin-6  loaded  particle,  non-
targeted coumarin-6 loaded particles loaded, and empty nanoparticles.  We harvested 
the organs three hours post injection, but did not see any difference in fluorescence 
between targeted and non-targeted treatments (data not shown).
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CD4 Targeting Flow Cytometry
Since  we  were  using  nanoparticles  with  CD4  targeting  through  the  RM4-4 
antibody,  we  wanted to  determine  if  specific  targeting  was  actually  occurring  in  our 
system.  We examined in vitro CD4 targeting using flow cytometry.  Splenocytes were 
cultured in seven groups (n=1/group) with staining using CD3-PE in the FL2 channel, 
CD4-PerCP-Cy5 in the FL3 channel and CD11c-APC in the FL4 channel.  Treatment 
groups  were  the  following:  no  treatment,  high  (0.1mg/ml)  and  low  (0.01mg/ml) 
concentrations each of CD4-targeted particles without coumarin-6, non-targeted isotype 
control (to RM4-4) coumarin-6 loaded particles, and CD4-targeted coumarin-6 loaded 
particles.  The results are reported as high and low concentrations of each particle group 
(Figure  8,9).   The  targeted  coumarin-6  particles  showed  greater  mean  fluorescent 
intensity in both high (MFI = 157) and low concentrations (MFI = 52) when compared to 
equivalent  concentrations  of  non-targeted  coumarin-6  loaded  particles  (high 
concentration MFI = 62, low concentration MFI = 27), suggesting the effectiveness for 
targeting CD4 cells with nanoparticles (Figure 8).  When the CD3+CD4+ cell population 
was gated upon similar trends were revealed with increased mean FL1 fluorescence in 
the CD4 targeted groups (high concentration MFI = 636, low concentration MFI =  176) 
vs non-targeted groups (high MFI = 83, low MFI = 24) (Figure 9).
The experiment  was repeated in  an  ex vivo model  in four groups (n = 3 per 
group) using a single dose (5mg of injected particle) of each particle group instead of a 
high and low dose (as in the in vitro).  Animals had their spleens harvested four hours 
after the injection of the treatments.  Mixed splenocytes were stained using CD11c-PE in 
the FL2 channel and CD4-PerCP-Cy5 in the FL3 channel.  The trends were maintained 
in this experiment as compared with the in vitro data, with increased mean FL1 
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fluorescence in the CD4-targeted groups (MFI = 26.8±10) as compared to the control 
(MFI = 3.5±0.75) (Figure 10).  However, despite much greater mean fluorescence in the 
CD4 targeted group, it was approaching statistical significance (p=0.08), but was found 
to be similar to both the isotype control-coumarin-6  loaded (MFI = 10.9±1.6) and the 
control, likely due to one low outlier in the CD4 targeted group (Figure 10).  In these 
same splenocytes stained for CD11c (in the FL2 channel) and CD4 (in the FL3 channel), 
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Figure 8.  Bar graphs showing 
comparisons between FL1 channel 
expression (coumarin-6) between 
low and high concentrations 
(0.1mg/ml and 0.01mg/ml) of CD4-
targeted and non-targeted 
nanoparticles.   Isotype control was 
used as comparison to RM4-4 CD4 
targeting antibodies.  Splenocytes 
were collected from naïve mice, 
were cultured in vitro with 
treatment groups and stained with 
CD3-PE in FL2, CD4-PerCP-
PECy5 in FL3 and CD11c-APC in 
FL4. N=1 per group
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Figure 9.  A. CD3 (FL2 channel) and CD4 (FL3 channel) gating showing a distinct CD3+CD4+ double positive 
population in the untreated control.  B.  Comparison of FL1 channel expression (coumarin-6) in the CD3+CD4+ double 
positive population between hi and low concentrations (0.1mg/ml and 0.01mg/ml ) of CD4-targeted, non-targeted 
nanoparticles loaded with coumarin-6 and CD4-targted particles not loaded with coumarin-6. Splenocytes were cultured 
in vitro with treatment groups and stained with CD3-PE in FL2, CD4-PerCP-PECy5 in FL3 and CD11c-APC in FL4. N=1 
per group
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it  was  found  that  a  higher  percentage  of  FL1  (coumarin-6)  fluorescent  cells  are 
CD4+CD11c-  in  the  CD4-targeted  group  (17% in  CD4-targeted  vs  10% in  the  non-
targeted group)(Figure 11, Quadrant 1).  In the non-targeted group, a higher percentage 
of FL1 fluorescent cells were CD11c+CD4- (9.4% in the non-targeted vs 4.6% in the 
CD4-targeted) (Figure 11, Quadrant 3). 
BALB/C to C57BL/6 grafts
To determine the effectiveness of the MPA-loaded nanoparticles in modifying the 
transplant  rejection  response,  we  first  examined  a  full  MHC  mismatch  BALB/C  to 
C57BL/6 skin transplantation (Figure 12).  As expected, rejection overall was rapid in our 
controls, but in this system we found significantly delayed graft rejection in non-specific 
nanoparticles (NP-MPA, 1ug MPA loaded per mg NP, 5 mg NP-MPA dosed per mouse 
on day 0,4,7,10,14,21; n=4) with a MST of 16 days compared with a MST of 13.5 days in 
the control (p<0.01).  The CD4-targeted treatments of MPA loaded nanoparticles (CD4+-
Figure 10. Ex vivo study looking at CD4 targeting in nanoparticles after collection of splenocytes from mice 4 
hours post injection with treatment groups and stained with or CD11c-PE (FL2 channel), CD4-PerCP-Cy5 (FL3 
channel and Thy1.2-APC (FL4 channel). FL1 measures coumarin-6 in nanoparticles.  Animals were injected with 
PBS, empty CD4-targeted nanoparticles (5mg particles), coumarin-6 loaded particles (5mg particles) with 
isotype control or CD4 targeted coumarin-6 loaded particles (n=3 for each group).  There was more fluorescence 
in the CD4-targeted particles than in the control and isotype controls, but due to one outlier, the increases in 
fluorescence were not statistically significant despite a large difference in mean fluorescence intensity.
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NP-MPA, 0.5 ug anti- CD4+ Ab [clone RM 4-4] conjugated per mg NP-MPA, 5 mg CD4+-
NP-MPA dosed per mouse on day 0,4,7,10,14,21; n=4) had an even greater delay with a 
MST of 25 days (p<0.01 compared with the control).  The survival for the CD4-targeted 
nanoparticles was significantly greater than for the non-targeted particles (MST 25 days 
vs  16  days,  p<0.05).   The  rejection  in  free  MPA (5  mg  per  mouse  dosed  on  day 
0,4,7,10,14,21;  n=4)  and controls  was statistically  the same with a MST of  15 days 
(p=0.06 compared with the control).   Mouse skin grafts showed rapid scabbing with 
eventual shedding of all grafts in all treatment groups (Figure 12).  
Figure 11. Ex vivo 
experiment where mice 
(n=3) were injected with 
treatments and 4 hours 
post injection splenocytes 
were harvested and 
stained for or CD11c-PE 
(FL2 channel), CD4-
PerCP-Cy5 (FL3 
channel) and Thy1.2-APC 
(FL4 channel).  After 
negatively gating the 
FL1+ population from 
controls, FL1+ subgroups 
were examined for CD4 
and CD11c.  In the 
targeted nanoparticle 
group, a higher 
percentage of the FL1+ 
cells were CD4+CD11c- 
than in the non-targeted 
group. 
Non Targeted C6 NP
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BALB/C to C57BL/6 MLR
To  further  characterize  the  phenotype  that  we  observed  with  in  vivo  skin 
transplants, we determined lymphocyte proliferation via a recall antigen  ex vivo MLR. 
We looked at  differences between  treatment  groups  (Free MPA 5mg/injection,  CD4-
targeted  MPA  nanoparticles  5mg/dose  and  non-targeted  MPA  nanoparticles  at 
5mg/dose)(n=4 per group) in post-transplant C57BL/6 CD4 enriched T cells stimulated 
with irradiated BALB/C splenocytes.  Mice had their spleens harvested at 35 days post-
transplantation.  There was an equal and large decrease in proliferation as measured by 
radioactive thymidine uptake in both the CD4-targeted and non-targeted animals (mean 
counts  per  minute  (CPM):  CD4-targeted  =  9627±36,  non-targeted  =  8812±696) 
compared with both the control (mean CPM = 24224±2169) and the empty nanoparticle 
(mean CPM = 20860±2083) (p<0.05 for both sets of comparisons) (Figure 13).
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Figure 12.  Full MHC mismatch BALB/C 
to C57BL/6 skin graft rejection in mice 
treated w ith f ree MPA (5 mg per mouse 
dosed on day 0,4,7,10,14,21; n=4), or 
NP-MPA (1ug MPA loaded per mg NP, 5 mg 
NP-MPA dosed per mouse on day 
0,4,7,10,14,21; n=4) or CD4+-NP-MPA 
(0.5 ug anti- CD4+ Ab (clone RM 4-4) 
conjugated per mg NP-MPA, 5 mg CD4+-
NP-MPA dosed per mouse on day 
0,4,7,10,14,21; n=4).  Control mice (n=4) 
received no additional treatment af ter 
skin grafting.  Free MPA failed to improve 
graft survival over the control (MST 15 
vs 13.5, p=0.06).  Non-targeted particles 
improved graft survival (MST 16, p<0.01). 
 CD4-targeting resulted in robust graf t 
prolongation (MST 25, p<0.01 vs control) 
also greater than the non-targeted 
(p<0.05)
Kassis, Elias                                                                                                           Page 45
We  also  looked  at  In  vitro MLR  with  C57BL/6  CD4  enriched  splenocytes 
cocultured with BALB/C irradiated splenocytes cultured for 72 hours in each treatment 
group (Free MPA at 10ug/ml, 1ug/ml, 0.1mg/ml; N-MPA and empty-NP at 0.1mg/ml and 
0.01mg/ml and control)(n=3 per group) and found a significant decrease in proliferation 
in free MPA groups in a dose dependent manner (Figure 14) (MPA 10mg/ml mean CPM 
= 42.5±6.3, MPA 1mg/ml mean CPM =76.6±36.6, MPA 0.1mg/ml mean CPM =329±54.7) 
compared to the control group (mean CPM = 8708±840) (p<0.05 for each MPA dose vs 
the control).  Nanoparticles loaded with MPA also showed a dose dependent decrease in 
proliferation  (NP-MPA 0.1mg/ml  mean  CPM  =  80.7±24.4,  NP-MPA 0.01mg/ml  mean 
CPM=1880±58.9)  compared  with  the  control  (p<0.05  for  each  group).   Empty 
nanoparticles showed a much greater proliferation response (NP 0.1mg/ml mean CPM= 
5582±850, NP 0.01mg/ml mean CPM=7104±278) than the equivalent concentrations of 
MPA-loaded  particle  (NP  vs  NP-MPA  at  0.1mg/ml,  p=0.003;  NP  vs  NP-MPA  at 
Figure 13.  Ex vivo enriched CD4+ T 
cells isolated and pooled from mice 
(n=4) in each treatment group (Free 
MPA 5mg/injection, targeted and non-
targeted 5mg/injection)on day 35 
post-transplant w ere cultured in 
complete Bruff ’s media for 56 hours 
in 96-w ell plates at 1x105 cells per 
w ell along w ith irradiated BALB/c 
splenocytes (1x106 cells per w ell). 
3H-thymidine w as added for the last 
18 hours and uptake w as measured 
by a β  plate scintillation counter. 
Mean CPM for each group: control-
24224, empty NP-20860.  Mean 
counts per minute (CPM) w as 
statistically decreased  (p<0.003 **) 
in both CD4-targeted and non-
targeted treatments
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0.001mg/ml, p<0.0001) and a statistically similar proliferation with the controls (Figure 
14). 
B6.H-2bm12 to C57BL/6 grafts
In order to further test and characterize the efficacy of CD4 targeting delivery of 
MPA, we transferred to a single MHCII mismatch CD4 dependent system for both in vivo 
and in vitro studies.  We repeated skin grafts in B6.H-2bm12 to C57BL/6 mice (Figure 
15).  Both targeted CD4-NP-MPA (MST = 39days, p=0.0004) and non-targeted NP-MPA 
loaded (MST = 33days,  p=0.002)  nanoparticles show significantly delayed transplant 
rejection as compared with no treatment (MST = 19.5 days).  Targeted (p=0.01) and non 
targeted MPA loaded (p=0.05) particles also show delayed rejection when compared to 
intermittent free MPA dosing (MST = 22 days).  There was no statistical difference in 
graft survival between the targeted and non-targeted MPA groups.  Daily free dosing 
(MST  =  26  days)  showed  no  significant  difference  in  survival  compared  with  the 
intermittent free MPA and both CD4-NP-MPA and NP-MPA.  Daily free MPA delayed 
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lls Figure 14. In vitro enriched splenic CD4+ T cells from naive B6 mice were co-cultured with 
irradiated BALB/c splenocytes in a one-way 
MLR without added treatment or treatment 
with free MPA, graded doses of empty NP 
(NP), or graded doses of NP encapsulated 
MPA (NP-MPA).  NP were encapsulated with 6 
μg of MPA per mg of NP.  Compared to no 
treatment, empty NP had no significant effect 
on T cell proliferation at either dose of NP (NP 
0.1 mg/ml, P=0.06; NP 0.01 mg/ml, P=0.14), 
whereas compared to no treatment, NP 
encapsulated MPA inhibited proliferation at 
both doses (NP-MPA 0.1 mg/ml, P=0.005; NP-
MPA  0.01 mg/ml, P=0.001).   For comparison 
of NP vs. NP-MPA, * denotes  P=0.0001 and 
** denotes P=0.003.  Graph only shows one 
dose of free MPA as the other doses were 
similar and equally low
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rejection as compared with the control as well (p= 0.01).  Targeted empty (MST = 18) 
and  non-targeted  empty  nanoparticles  (MST  =  20)  had  similar  graft  rejection  as 
compared with the no treatment group (Figure 15).  In this less immunogenic model (as 
compared to BALB/C to C57BL/6), overall graft rejection was less rapid, but complete 
rejection was still found in all treatment groups.
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Figure 16. Skin graft survival 
data in B6.H-2bm12 graft to 
C57BL/6 host mice treated 
with PBS (control)  B6.H-
2bm12 graft to C57BL/6 host 
mice ttreated with GK1.5 
depleting antibody, or  B6.H-
2bm12 graft to C57BL/6 -CD4 
k/o host mice.  CD4 k/o 
accepted grafts indefinitely.  
GK1.5 treated mice had 
statistically increased MST of 
32 days over control mice 
MST of 19.5days (P<0.006).
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Figure 15. Skin graft survival in B6.H-2bm12 graft 
to C57BL/6 host mice, single MHCII mismatch 
model. Mice were treated with free MPA (5 mg per 
mouse dosed on day 0,4,7,10,14,21; n=6), or NP-
MPA (1ug MPA loaded per mg NP, 5 mg NP-MPA 
dosed per mouse on day 0,4,7,10,14,21; n=11) or 
CD4+-NP-MPA (0.5 ug anti- CD4+ Ab (clone RM 
4-4) conjugated per mg NP-MPA, 5 mg CD4+-NP-
MPA dosed per mouse on day 0,4,7,10,14,21; 
n=11.  Control mice received no additional 
treatment (n = 10).  Mean survival times (MST) 
was significantly increased in both CD4-targeted 
(MST 39, p=0.0001) and non-targeted (MST 33, 
p=0.002)MPA-particles  compared with NoRx 
mice (MST 19.5).  Both targeted and non-targeted 
MPA-particles increased MST over intermittent 
free MPA (MST 22, p<0.05) but not over daily free 
MPA(MST 26).  Targeted and non-targeted MPA-
particles had similar MST.  All controls had similar 
MST(18-20 days). 
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CD4 k/o and GK1.5 Transplantation
Rejection  in  B6.H-2bm12 to  C57BL/6  graft  was  shown  to  be  a  CD4,  MHCII 
dependent  process.   We looked at  skin transplants  in  a CD4 knockout  mouse on a 
C57BL/6 background receiving a B6.H-2bm12 skin graft. CD4 knockout mice failed to 
reject  their  skin  grafts,  with  eventual  complete  graft  acceptance  (Figure  16). 
Furthermore, in animals treated with GK1.5, an antibody to CD4 that inhibits function, we 
found delayed graft rejection (MST =32 days, p<0.006) as compared with control groups 
(MST 19.5 days).  However all animals treated with GK1.5 eventually had complete graft 
rejection (Figure 16).  
Rejection Histology
In order to observe the cellular response within the graft and the differences in 
response between treatment groups, skin graft biopsies were collected for histology on
 
A. B. C.
D. E.
Figure 17.  Representative skin graft 
histology from day 15 post transplantation 
with H+E staining.  Images are all at 10x 
magnification.  A.  No Treatment control 
mice showing a robust inflammatory 
response.  B.  Free intermittent MPA 
treatment also showing signs of rejection 
with infiltration and inflammatory cells.  C.  
Non-targeted MPA-nanoparticles showing 
decreased inflammation qualitatively 
compared with control.  D. CD4-targeted 
MPA nanoparticles showing decreased 
inflammation compared to controls.  E.  
CD4-targeted empty nanoparticles showing 
inflammation and signs of graft rejection.  
Arrows indicate areas of inflammation, stars 
indicate skin sloughing off.
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day 15 from representative mice within each treatment group.  Histology of the skin graft 
showed increased inflammation  and cellular  infiltration  with increased signs  of  acute 
rejection.   The targeted and non-targeted MPA-loaded nanoparticle  treatment groups 
exhibited  less  lymphocytic  infiltration  and  decreased  overall  signs  of  acute  rejection 
(Figure 17).  The observations were qualitative and no formal scoring system was used 
for comparison.  
B6.H-2bm12 to C57BL/6 MLR 
Lymphocyte proliferation and the effect of  MPA and MPA-loaded particles was 
also examined via MLR and showed a decrease in proliferation after culture with MPA-
loaded  nanoparticles.   Our  in  vitro MLR used  C57BL/6  splenocytes  cocultured  with 
B6.H-2bm12 bone marrow derived dendritic cells that had been been previously cultured 
with increasing free MPA concentrations, increasing empty particle and increasing MPA-
loaded  particle  concentrations  (Figure  18).   NP-MPA  at  0.1mg/ml  (mean  CPM 
Figure 18.  C57BL/6 splenocytes were CD4+ T 
cell enriched and cocultured in a one-way 
MLR with  B6.H-2bm12 BMDCs that had been 
previously cultured for 24h with LPS, free 
MPA, empty NP or NP-MPA at increasing 
concentrations listed in the figure in 96-well 
plates at 1x10^5 cells per well along with the 
irradiated  DC's  (1x10^6  cells per well). 3H-
thymidine was added for the last 24 hours and 
uptake was measured by a β plate scintillation 
counter.  Mean CPM was decreased in all 
concentrations of nanoparticles loaded with 
MPA (NP-MPA) (p<0.03 * for each 
comparison) compared with control.  NP-MPA 
at all concentrations was decreased compared 
with free MPA at all concentrations as well 
(p<0.05 * for each comparison).
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=2808±261, p<0.01),  at  0.01mg/ml (mean CPM = 3484±457, p<0.02) and 0.01mg/ml 
(mean  CPM  =3071±1026,  p<0.03)  were  all  significantly  decreased  from  the  control 
(mean CPM = 8918±794).  NP-MPA treated groups were also significantly decreased 
(p<0.05) from the free MPA groups (MPA 0.1mg/ml CPM = 7136±458, MPA 0.01mg/ml 
CPM = 6294±565, MPA 0.001mg/ml CPM = 7930±1098) (Figure 18).  Due to a problem 
with the extraction, the ex vivo results were not interpretable for comparison. 
Particle Uptake in Dendritic Cells
As we hyopthesized that dendritic cells were involved in the phenotype that we 
A. B. C.
D. E. F.
Figure 19.   Incubation of cultured DC's collected from bone marrow with nanoparticles for 2 hours 
with images obtained at 20x magnification using a fluorescent microscope  A. Shows coumarin-6 
fluorescence in the green-fluorescent channel in loaded-nanoparticles incubated with DC's.  B.  
DAPI counter-staining of the nucleus in the coumarin-6 loaded incubation. C. Overlay of green 
and blue channels coumarin-6 and DAPI staining shows nanoparticles in attached to cell surface, 
within the cytosol and possibly at different stages of phagocytosis.  D. Green-channel 
fluorescence in DC's cultured with empty particle control. E. DAPI nuclear counter stain.  F. 
Overlay of green and blue channel in empty particles.
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observed with similar graft rejection between targeted and non-targeted nanoparticles, 
we  wanted  to  see if  DCs  would  take  up  nanoparticles  while  in  culture.   DCs  were 
incubated on slides overnight for attachment.  Uptake of nanoparticles was examined by 
comparing DCs cultured with coumarin-6 loaded particles with empty particles at 2 hours 
and 18 hours  of  incubation.   At  both  2  hours  and 18 hours  the  coumarin-6  loaded 
particle-treated groups showed increased DC uptake of  nanoparticles with increased 
fluorescent signal compared to the controls (Figure 19).  Furthermore, the fluorescent 
signal  appeared  to  be  both  diffusely  increased  in  the  cytoplasm  as  well  as  focally 
increased in nanoparticles attached to the cell  membrane in what  may appear to be 
varying stages of phagocytosis (Figure 19).  
Cytokine Activation
To characterize the inflammatory response and the modulation that we expected 
to  find  with  treatment  using  MPA-loaded  nanoparticles,  we  also  looked  at  cytokine 
profiles.  The supernatant from MLR with culture of pre-treated DCs from B6.H-2bm12 
mice with CD4 enriched C57BL/6 cells was analyzed for IL-2 production via ELISA.  IL-2 
production  appeared  to  be  decreased  in  a  dose  dependent  fashion  with  increasing 
doses of MPA-loaded nanoparticles (N-MPA0.1mg/ml mean IL-2 concentration = 382±17 
pg/ml, p<0.005; N-MPA 0.01mg/ml mean IL-2 concentration = 523±62 pg/ml, p<0.02; N-
MPA0.001mg/ml  mean  IL-2  concentration  =  636±6  pg/ml,  p<0.01)  compared  to  the 
control (Figure 20).  Increasing doses of free MPA also showed decreased production in 
a  dose  dependent  manner  (MPA10ug/ml  mean  IL-2  concentration  =  262±11  pg/ml, 
p<0.004; MPA1ug/ml mean IL-2 concentration = 661±10 pg/ml,  p<0.01; MPA0.1ug/ml 
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mean  IL-2  concentration  =  695±24  pg/ml,  p<0.02;  MPA0.01ug/ml  mean  IL-2 
concentration = 800±46 pg/ml,  p<0.03) compared with the control  (No Rx mean IL-2 
concentration = 1251±57 pg/ml).  (Figure 20).  IFN-gamma levels (although we expected 
them to be low) were unchanged between treatment groups, nor did we find an increase 
in IL-10 production in the MPA-loaded particles (data not shown).  Overall numbers were 
low in these experiments and were therefore difficult to interpret.
In  addition to  the MLR cytokine production,  we also looked at  the profiles of 
activated dendritic cells in the presence or absence of NP treatments.  DCs that were 
pre-treated with free MPA, empty particles,  MPA-loaded particles and control  groups 
were then stimulated with LPS and production of IL-6 and IL-12 was measured (Figure 
21).  IL-6 cytokine production was significantly decreased in N-MPA at all concentrations 
(N-MPA0.1mg/ml  mean  IL-6  concentration  =  63738±4055  pg/ml,  p<0.05;  N-
MPA0.01mg/ml mean IL-6 concentration = 53339±3664 pg/ml, p<0.05) compared with 
the NoRx +LPS control (mean IL-6 concentration = 132671±2295 pg/ml).  Free MPA was 
also  found  to  decrease  IL-6  production  (MPA9ug/ml  mean  IL-6  concentration  = 
Figure 20.  IL-2 production from 
MLR coculture of B6.H-2bm12 
DC's at 1x106 cells/well with 
C57BL/6 CD4 enriched 
splenocytes at 1x105 cells per 
well after treatment of DC's with 
increasing doses of free MPA, 
nanoparticles encapsulating MPA 
and empty nanoparticles.  Free 
MPA at all concentration showed 
a decrease in IL-2 production 
compared with control (p<0.03* 
for each comparison)  N-MPA at 
all concentrations decreased IL-2 
(p<0.02 ** for all comparisons).
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40815±1661 pg/ml, p<0.01; MPA0.9ug/ml mean IL-6 concentration = 43483±1855 pg/ml, 
p<0.01) compared with the control.  IL-12 was also reduced in one experiment by doses 
of N-MPA (N-MPA0.1mg/ml mean IL-12 concentration = 22306±141pg/ml,  p<0.05; N-
MPA0.01mg/ml mean IL12 concentration = 44919±871 pg/ml, p<0.05).   Free MPA was 
also able to decrease IL-12 at 9mg/ml (mean IL-12 concentration= 36054±270 pg/ml, 
p<0.05) and 0.9mg/ml (mean IL-12 concentration = 54403±900 pg/ml, p<0.05) (Figure 
21).  We did not find any up-regulation of IL-10 in these tests either, and downregulation 
of TNF was also not seen (data not shown).
DC Maturation Markers
As we thought that MPA-loaded nanoparticles may be affecting dendritic cells, we 
also looked for any changes in costimulatory and maturation surface markers on DCs 
Figure 21. IL-12 and IL-6 production from DC's.  DC's were collected from 
C57BL/6 bone marrow grown for 5 days, incubated with treatment groups for 24 
hours, and subsequently stimulated with LPS for an additional 24 hours.  Both 
free MPA and Nanoparticles encapsulating MPA showed a decreased production 
of both IL-12 and IL-6 compared with control (p<0.05 *).   
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after treatment.  Draining lymph nodes from transplanted mice were harvested on day 15 
and cells were stained for DC maturation markers with CD40-FITC, CD80-FITC, MHCII-
PE  and  CD86-APC.   Cells  were  run  on  flow cytometry  to  determine  differences  in 
surface expression and gated on CD11c+ populations.  CD40, CD80 and MHCII surface 
expression was unchanged in animals treated with free MPA, non-targeted-nanoparticles 
loaded with MPA and CD4-targeted nanoparticles (Figure 22).  CD86 expression was 
significantly decreased in both targeted (MFI = 38±2, p<0.005) and non-targeted (MFI = 
39±3, p<0.02) MPA-loaded particle treatment groups (n=3/group) (Figure 22).  In vitro 
DCs were also stained with CD80, CD86, CD40 and MHCII after 3 days of proliferation 
and subsequent 24 hours of treatment with free MPA, N-MPA and empty particles, and 
no differences were found in surface expression in the CD11c gated population (data not 
shown).
Figure 22.  Draining 
lymph nodes were 
collected from mice on 
day 15 post-transplant.  
Lymphocytes were 
stained ex vivo with DC 
maturation markers 
CD40-FITC, MHCII-PE, 
CD80-FITC and CD86-
APC. There were no 
difference in CD40 (A), 
MHCII (B) or CD80 (C) 
between groups.  D.  
CD86 showed a 
significantly decreased 
CD86 surface expression 
via mean fluorescence 
intensity (MFI) with both 
targeted and non-
targeted treatments (n=3, 
p<0.05) compared with 
controls (stars = p<0.05).  
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Treg proliferation
Regulatory  T  cells  have  been  shown  to  be  involved  in  decreased  immune 
responses  to  transplantation  (64),  so  we  also  looked  for  increases  in  Tregs  after 
treatment  with  MPA-loaded  nanoparticles.   At  day  21  post-transplant  we  collected 
splenocytes from our treatment mice (Free 5mg MPA, targeted and non-targeted N-MPA 
at 5mg particle) and stained the cells ex vivo with CD4-APC (FL4 channel), CD25-FITC 
(FL1 channel) and Foxp3-PE (FL2 channel).  We gated on side and forward scatter for 
lymphocytes and looked at the CD4+CD25+ population of cells and compared mean 
fluorescence intensity of Foxp3 (FL2).  We found an increased MFI in free MPA (MFI = 
Figure 23.Ex vivo 
splenocytes were 
collected at day 21 post-
transplantation and were 
stained with CD25-FITC, 
CD4-APC and foxp3-PE 
Lymphocytes were gated 
with FSC and SSC, and 
foxp3  (FL2) mean 
intensity (MFI) was 
compared between 
treatment groups 
(n=3/group).  Free MPA 
and NP-MPA showed 
significant increases in 
fluorescence (p<0.05 *) 
and CD4-NP-MPA showed 
highly significant increase 
in fluorescence 
(p<0.003**)
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111±11, p<0.05) in non-targeted particles (MFI =  94±5, p<0.05) and in CD4-targeted 
particles (MFI = 115±4, p<0.003) (Figure 23).   
Apoptosis Flow Cytometry
 To determine if there were increases in dendritic cell death through apoptosis, we 
collected DCs after incubation with our treatment groups for flow cytometry.  We stained 
DCs with 7-AAD (FL3 channel),  Annexin (FL1 channel) and CD11c-APC (FL-4).   We 
gated on a DC population using forward and side scatter  and subgated on the FL4 
channel  to  capture  CD11c+  cells,  and  determined  relative  percentage  of  cells 
undergoing apoptosis in each group (Figure 24). Apoptotic cells were determined as 7-
AAD negative, Annexin positive.  There was more apoptosis in both MPA loaded  (10% 
7AAD-Annexin+) and empty nanoparticles (9% 7AAD-Annexin+) at high concentrations 
Figure 24.  DC's incubated with treatment groups were collected and stained with annexin (FL1), 
7AAD (FL3) and CD11c-APC(FL4).  Populations were gated on DC population via SSC vs FSC and 
gated further on CD11c+ populations.  Apoptotic cells were considered 7AAD negative, Annexin 
positive. A.  Diagram showing FL1 vs FL3 channels.  B.  graph of percentage of cells from the third 
quadrant of every treatment group showing increased apoptosis in N-MPA groups.  (n= 1 for each 
group)   
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(0.1mg/ml) without sufficient data to run statistics (n=1 per group) (Figure 24).
B7-DC and B7-H1 Flow Cytometry
B7-DC and B7-H1 have  been shown to  be  important  negative  co-stimulatory 
molecules that may be involved with dendritic cell decrease in T cell antigen response. 
We were interested to determine if these molecules were involved with the phenotype 
that we observed in our system.  In DCs that were pretreated with MPA-loaded particles,
 
empty  particles,  free  MPA and  no  treatment,  we  found  consistently  elevated  mean 
Figure 25.  Mean fluorescence intensity of DC's  stained with B7DC-FITC and B7H1-PE.  A,B.   Results from first 
experiment (n=1 for each group) with increased expression in the 0.2 mg/ml MPA-NP group.  C,D.  Experiment was 
repeated with two different mice showing a consistent increased expression of both B7-DC and B7-H1 on DC's treated 
with MPA-loaded nanoparticles (at 0.1 mg/ml) and gated on CD11c+ population.  In the second experiment, B7-DC and 
B7-H1 fluorescence were both statistically increased compared with the control group (p<0.05 *).  Data was not 
combined between the first and second experiments due to difference in gating and staining.
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fluorescence looking at  B7-H1 and B7-DC surface expression in  groups treated with 
0.1mg/ml MPA-loaded particles.  Our initial experiment (n=1) showed this trend in both 
B7-DC (NP-MPA0.1mg/ml fluorescence = 158, control  fluorescence = 68) and B7-H1 
(MPA0.1mg/ml fluorescence = 1424, control fluorescence = 842) (Figure 25).  Repetition 
of the experiment with an additional two animals confirmed the results with significant 
increase in surface expression of both B7-DC (MFI = 134±21, p<0.05) and B7-H1 (MFI = 
146±16, p<0.05) compared with the control (Figure 25). 
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Discussion
Summary
MPA-loaded particles showed a slow and continuous release profile in vitro and 
biodistribution demonstrated a possible increased nanoparticle retention in the spleen. 
We showed effective targeting of nanoparticles to CD4 T cells using both ex vivo and in 
vitro analysis  by flow cytometry.   In  the fully  allogeneic  MHCII  mismatch BALB/C to 
C57BL/6 mice we found improved graft survival in the non-targeted MPA group and even 
greater graft survival in the CD4-targeted group, as well as decreased proliferation with 
both  targeted  and  non-targeted  nanoparticles  using  in  vitro and  ex  vivo mixed 
lymphocyte reactions.  In the less immunogenic B6.H-2bm12 to C57BL/6 transplants, a 
single MHC-II mismatch model, we found equal and increased graft survival in both the 
CD4 targeted  and  non-targeted  animals.   In  both  the  highly  immunogenic  and  less 
immunogenic  models,  graft  survival  times  were  increased  over  free  drug  using  the 
nanoparticle  encapsulation  and the  total  dose of  drug given to attain  this  increased 
survival was roughly one thousand fold lower than the free drug concentration.  We also 
showed that the B6.H-2bm12 to C57BL/6 model was CD4 dependent by administration 
of the depleting antibody GK1.5 and by transplanting skin from a B6.H-2bm12 mouse 
onto CD4 knockout mouse bred onto a C57BL/6 background.  It was postulated that the 
similar rejection times in targeted and non-targeted groups was due to dendritic cell (DC) 
involvement  and  we  found  active  uptake  of  nanoparticles  in  DCs,  a  decrease  in 
inflammatory cytokine production and a decrease in treated DCs ability to stimulate T 
cells via mixed lymphocyte reactions.  Furthermore we found a possible mechanism of 
nanoparticle-MPA action on the DC interaction with T cells through the upregulation of 
the inhibiting co-stimulatory molecules B7-DC and B7-H1 on DCs treated with MPA-
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nanoparticles.  These ligands bind the PD-1 receptor on activated T cells and have been 
implicated in a decreased immune response.  We also found possible upregulation of 
CD4+CD25+ Foxp3  expressing T cells which may serve to increase graft acceptance. 
These results indicate the feasibility of  nanoparticles loaded with immunosuppressive 
drugs to be used clinically and illustrate the involvement of dendritic cells in the process 
of nanoparticle induced graft acceptance.
B6.H-2bm12 to C57BL/6 Survival
The results of our graft survival show that CD4-targeted and non-targeted MPA 
loaded particles significantly delay graft rejection by two to three weeks over the control 
groups.   The results also showed that targeted particles do not significantly delay graft 
rejection  over  non-targeted  particles  despite  a  mean  survival  time  increase  of  an 
additional six days in the B6.H-2bm12 to C57BL/6 transplants.  It is possible that the 
study was under-powered to show subtle differences between these two groups, but it is 
also  possible  that  there  is  no  actual  difference  between  targeted  and  non-targeted 
nanoparticle treatments with both groups working very well to delay transplant rejection. 
The  intermittent  free  drug  was  significantly  less  effective  at  decreasing  graft 
rejection as compared with the MPA-loaded particles.  Mycophenolate mofetil in its oral 
form exhibits peak blood concentrations of MPA at 1-2 hours after conversion in the liver 
to its active form.  It also exhibits a mean half-life between 9-17 hours, with great inter-
subject variability.  Because of this, it is generally dosed twice a day in humans  (65). 
Therefore, our intermittent free drug treatments were large doses  quickly cleared by the 
mouse.  Due to this clearance, there were multiple days where MPA blood levels were 
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likely  very  low  until  the  next  treatment  with  MPA.   We  did  not  examine  the 
pharmacokinetics of MPA in our mice, but we thought that the intermittent dosing was 
not an optimal comparison to our nanoparticles despite the thousand fold lower dose in 
the nanoparticles.  To address this we included in our study a daily intermittent dosing in 
one of our later transplant groups.  Due to the low number of animals in this treatment 
group  we  did  not  achieve  a  statistically  significant  difference  in  mean  survival  time 
compared to either the intermittent free MPA or with either of the MPA encapsulated 
nanoparticles, even though the MST was four days longer than the intermittent free drug 
and  13  days  shorter  than  the  MST  for  targeted  nanoparticle  treated  groups. 
Nevertheless, it is interesting that daily free drug in doses that are more than a thousand 
fold greater STILL do not show improved graft survival than the nanoparticle delivered 
MPA.  This is consistent with literature showing that nanoparticle encapsulated drugs 
can  be  conveyed  with  better  efficacy  due  to  the  delivery  characteristics  of  the 
nanoparticles  (59).  Furthermore, our results agree with literature showing that single 
dose injections of PLGA nanoparticles encapsulated with drug can have equal  in vivo 
efficacy  as  daily  injected  doses  of  the  drug  (42).   Some  studies  have  even  found 
improved efficacy of single dose PLGA nanoparticle injections as compared with multiple 
free drug injections  (66).  This delay in graft rejection is also clearly not secondary to 
effects of the empty nanoparticles alone as empty particles that are targeted and non-
targeted show the same mean survival time as the non-treated group.  In addition, the 
histology confirms the robust inflammatory response seen in the control groups and the 
decrease  in  cellular  infiltration  and  inflammation  in  the  nanoparticle-MPA treatment 
groups with delayed rejection.
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BALB/C to C57BL/6
It  is also interesting that in our small data set using BALB/C to C57BL/6 skin 
transplants, we found significantly greater graft survival in the targeted MPA-nanoparticle 
group when compared to the non-targeted MPA-nanoparticle  group.   This  difference 
might represent the small numbers of animals in each group and be due to insufficient 
power,  but  it  may  also  represent  a  different  phenotype  as  compared  with  the  less 
immunogenic  B6.H-2bm12 to C57BL/6 transplants (as the difference was statistically 
significant with a p<0.05).  In skin-grafted mice, the migration of MHC class II  donor-
derived dendritic cells (DCs) to the recipient’s lymph nodes triggers a potent direct CD4 
T cell alloresponse.  Skin grafts can be rejected directly or indirectly by both CD4 and 
CD8 cells activated against both MHC and minor antigens in a major mismatch model 
such as a BALB/C to C57BL/6 skin transplant.  Interestingly however, one group that 
looked at   B6.H-2bm12 to C57BL/6 skin grafts found only the direct allopresentation 
response in their model  (62).  This is of interest within our study due to the phenotypic 
difference in rejection between the highly immunogenic BALB/C to C57BL/6 and the less 
immunogenic B6.H-2bm12 to C57BL/6 graft.   If  the highly immunogenic model relies 
upon both direct and indirect allorecognition, and the indirect response is absent from 
the less immunogenic B6.H-2bm12 to C57BL/6 model, than perhaps this explains the 
observations  in  the  targeted  and  non-targeted  groups  in  both  models.   This  has 
interesting possible implications as it  may suggest  that  targeted nanoparticles in  the 
BALB/C to C57BL/6 affect the indirect pathway to greater degree (increasing MST in 
targeted  treatments)  and  with  this  presentation  pathway  absent  in  the  B6.H-2bm12 
transplants, perhaps this contributes to the similarity between targeted and non-targeted 
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groups.  This interaction has not been examined in the literature, but it may be worth 
further study.  To test this you could utilize models that isolate either the direct or indirect 
pathways, and compare targeted and non-targeted nanoparticle treatments within each 
model.   These models  may be created using transgenic  mice (such as  CD11c-DTR 
transgenic mice that can be conditionally depleted of CD11c+ DCs with administration of 
diphtheria)  that  impair  DC  function/antigen  presentation  (back-crossed  or  bred  on 
BALB/C,  C57BL/6  and  B6.H-2bm12  mice)  as  both  donor  and  recipient  mice.   The 
indirect pathway may be isolated using our current models with depletion of donor DCs 
within the skin graft before prior to transplantation.  These may be interesting avenues of 
study because if the indirect pathway is affected more by targeted nanoparticles, this 
could have implications for  the elusive treatment of  chronic rejection,  as the indirect 
pathway has been implicated in chronic rejection pathogenesis(17).  
MLR interpretation
Interestingly,  despite the difference in targeted and non-targeted treatments  in 
vivo of graft survival times in the BALB/C to C57BL/6 mice, the ex vivo MLR on these 
animals showed a reduction in proliferation that was equal between the targeted and 
non-targeted  groups.   Although  the  flow  cytometry  data  likely  indicated  successful 
targeting with CD4-targeted particles, it is unclear how well targeting actually induces a 
down-regulation of alloimmune cells, as the decrease in proliferation was equal in the ex 
vivo targeted  and  non-targeted  groups.   This  finding  may  also  simply  represent  a 
difference between a transplant  response and a  MLR in  the behavioral  response to 
MPA-loaded particles and be an artifact of the assay itself.  Unfortunately, the  ex vivo 
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data from our B6.H-2bm12 transplants were not interpretable after technical problems 
during the radioisotope extraction, so we are not able to compare  in vivo to  ex vivo 
results in the B6.H-2bm12 transplants.  The in vitro data from both transplant models are 
consistent showing a decreased proliferation with MPA-loaded particles.  Unfortunately, 
we were not able to test the specific interaction of nanoparticles with CD4 T cells in our 
MLR as CD4 T cells remain in suspension and cannot be separated for subsequent 
culture with dendritic cells and splenocytes.  In the future we may attempt to flow-sort the 
sample to isolate T cells from suspension (as long as T cells are not non-specifically 
activated  by  flow  sorting).   In  our  BALB/C  model  the  co-incubation  of  irradiated 
splenocytes, CD4 T cells and treatment groups likely showed particle interactions with 
both CD4 T cells and the APCs in the splenocytes.  Initially we thought that irradiation of 
the splenocytes would decrease phagocytosis and lead to a response that was reliant 
upon the CD4 T cell  uptake of  nanoparticles,  but  there  does not  appear  to  be any 
literature that clearly shows that APC irradiation decreases phagocytosis, and therefore 
the response we found is likely due to nanoparticle interaction with both cell types.  In 
our B6.H-2bm12  in vitro  MLR's we found a response that  was dependent  strictly on 
pretreatment of DCs.  We cultured the nanoparticles with DCs before coculture with CD4 
T  cells  which  points  to  the  involvement  of  DCs  in  our  in  vivo  skin  graft  rejection 
phenotype.   Our  MLR's  therefore  were  able  to  show  nanoparticle  affects  on  the 
proliferative response through DCs but were not able to show an affect through CD4 T 
cells alone.  Overall however, the results of these MLR's are consistent with our graft 
survival data, and consistent with the observed in vitro changes in cytokine expression 
with an overall decreased inflammatory and proliferative response.  
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CD4 dependence and targeting
It was important to determine the CD4 dependent nature of the B6.H-2bm12 to 
C57BL/6 model, to make sure that the effect that we saw from treatment was secondary 
to CD4 T cell activity.  Using GK1.5 depleting antibody against CD4, we saw a modest 
increase in graft survival although a change that was less than expected (still statistically 
significantly greater than the control).  It is possible that the doses of antibody used were 
insufficient to decrease a proliferative response, and that a larger dose of GK1.5 would 
have increased mean graft survival longer.  Furthermore with only three animals in this 
group, we may have had too few animals to properly see the larger difference.  Using a 
CD4 knockout mouse as the recipient allowed for acceptance of the graft showing the 
CD4 dependent rejection in our model.  Since CD4 T cells regulate both the cytotoxic 
and humoral allospecific response of CD8 and B-cells, the CD4 knockouts likely have 
reduced overall immunity leading to graft acceptance.  The results of both our GK1.5 
and CD4 knockout mice are in agreement with a study looking at pancreas xenografts 
from rat to mouse that was shown to be CD4 dependent similarly to our model but in a 
different organ system and model.  GK1.5 treatments delayed graft rejection, while CD4 
knockout mice showed acceptance of the graft in a model that suggested dependence 
on CD4 cells for rejection (67).  
The discovery that non-targeted nanoparticles loaded with MPA displayed equal 
skin graft prolongation as the targeted particles in our B6.H-2bm12 to C57BL/6 mice was 
initially a surprise.  It is unclear if this lack of difference was due to poor targeting of the 
nanoparticles.   Targeting was suggested with the flow cytometry with  increased FL1 
channel signal in the targeted coumarin-6 particles as compared with the non-targeted 
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particles.  The ex vivo data were not shown to be significant however due to the small 
number  of  samples  (with  one  outlier)  and  this  needs  to  be  repeated  to  truly  prove 
targeting.  Despite this lack of significance, in the targeted nanoparticle group the FL1 
coumarin-6  positive  cell  population  had  an  increased  percentage  of  cells  in  the 
CD4+CD11c-  subpopulation.    In  the  non-targeted  nanoparticle  treatment,  the  FL1 
coumarin-6 positive  cell  population had an increased population  in  the  CD11c+CD4- 
subpopulation.   The  increased  number  of  coumarin-6  fluorescent  cells  in  the 
CD4+CD11c-  population  with  targeted  nanoparticles  indicated  that  specific 
binding/uptake in CD4 cells was likely greater than the non-specific/binding/uptake in 
DCs expressing CD11c.  In addition our collaborators have consistently found targeting 
with these same particles in their previous studies using anti-CD3 (48)(32) and in their 
unpublished data showing success with anti-CD4 targeting as well.  One question that 
remains unclear though (as it does with most flow cytometry comparisons) is how any 
observed difference in fluorescence would actually translate into a meaningful clinical or 
functional difference.  The data from our collaborators comparing retro-orbital injections 
of PEGylated rhodamine loaded PLGA particles compared with CD4 targeted particles 
showed increased retention in the spleen after injection in the targeted particles, but this 
data  is  difficult  to  interpret  as  it  was  only  done  in  one  mouse/group,  and  the  CD4 
targeted particles appeared to be retained in all organs to a greater degree than the non-
targeted particles.  These data would need to be repeated to determine any significance. 
Furthermore a difference in biodistribution alone would not prove targeting, but the large 
CD4 population in the spleen would explain any increased retention compared with non-
targeting.    The lack of difference in biodistribution that we found at three hours post 
intraperitoneal injection may be due to retention in the peritoneum (as opposed to direct 
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introduction into the vasculature with retro-orbital injections) and a longer time may be 
needed post injection to be able to find systemic differences in nanoparticle retention. 
Overall, our data suggests successful targeting, but needs to be repeated to determine 
the consistency of these findings.
Dendritic Cell Involvement
We  postulated  that  our  targeted  and  non-targeted  nanoparticles  may  be 
exhibiting  two  different  mechanisms  abrogating  graft  rejection  and  increasing  mean 
survival times of skin grafts in our B6.H-2bm12 model.  The CD4-targeted particles likely 
increase transplant acceptance through their activity directly on CD4 T cells via cytosolic 
delivery of MPA while the non-targeted particles induce acceptance through some other 
pathway that was initially unclear to us (with CD4-targeted particles likely acting through 
this pathway to some degree as well).  The flow cytometry data from our ex vivo animals 
showed  increased  FL1  signaling  and  hence  increased  binding/uptake  of  the  non-
targeted  particles  in  the  CD11c+CD4-  subgroup  that  makes  up  the  dendritic  cell 
population.  This indicated to us that dendritic cells possibly were actively taking up the 
non-targeted nanoparticles and suggested to us that the non-targeted particles may be 
yielding  their  effects  through  activity  on  the  dendritic  cells.   As  DCs  are  important 
scavengers and sentinels of the periphery with enormous influence on the fate of T cell 
populations (68), we speculated that uptake of nanoparticles into dendritic cells may be 
involved in our observed phenotype.  
It was suggested in one study that dendritic cells exert a powerful influence in 
skin graft transplant models due to the higher than normal numbers of dendritic cells that 
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are resident within skin compared with other tissues (62).  Dendritic cells in general have 
a great influence on transplant rejection, which has consistently been shown throughout 
the transplant literature.  The direct and indirect antigen presentation pathways have 
been  shown  to  be  vital  in  presentation  of  foreign  antigen  and  development  of  an 
allogenic immune response  (15) .  Dendritic cells exert their influence on the rejection 
process in multiple different ways, and are the important front-line cells in the detection 
and allospecific response to foreign antigens (68).  It has been shown that the peak size 
of the allospecific T cell population is an important factor in the speed and robustness of 
the rejection (69).  It has also been shown that an important factor in the peak size of 
this T cell population is the number of antigen presenting cells that are activated  (70), 
with larger numbers of activated DCs leading to a larger T cell response.    Overall, 
dendritic  cells  increase  the  transplant  response  through  their  direct  and  indirect 
activation of T cells, presentation of costimulatory molecules and production of excitatory 
cytokines (15).  
Dendritic cells have also been shown to be involved in the down-regulation of the 
transplant  rejection  immune response.   This  down-regulation  could  be  through  their 
absence, decreasing the number of activated antigen presenting cells and subsequently 
decreasing the alloreactive T cell population, but DCs have also been shown to directly 
down-regulate the immune response as well.  This action is through their production of 
ligands  for  negative  costimulation,  decreased  activation  of  T  cells  with  changes  in 
cytokine profiles and induction of tolerant anergic responses via immature dendritic cells 
and up-regulation of CD4+CD25+ regulatory T cells (71).  
MPA uptake via  nanoparticle  delivery may lead  to  inhibition  of  dendritic  cells 
which in turn would lead to decreased activation of graft specific T cells.  Our microscopy 
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of dendritic cells cultured with nanoparticles showed robust phagocytosis of the particles 
by  dendritic  cells.   Furthermore,  we  found  a  decreased  mixed  lymphocyte  reaction 
response with  B6.H-2bm12 dendritic  cells  treated  with  MPA-nanoparticles  cocultured 
with C57BL/6 CD4 cells.  This in vitro response indicated that dendritic cells were likely 
less  able  to  activate  T  cell  proliferation  after  the  DCs  had  been  exposed  to  MPA-
nanoparticles.   Qualitatively  it  was  also  noticed  that  the  DCs  treated  with  the 
nanoparticles appeared to be less healthy in appearance and formed fewer clusters in 
culture which may have been an indication of decreased function, and decreased ability 
to activate a T cell response.  In addition, we found decreases in inflammatory cytokine 
expression in  DCs cultured with MPA-particles.   With regard to the  in  vivo rejection 
response, these cumulative data suggested that DCs may have been responsible.
MPA and Dendritic Cells
Recently it was shown that dendritic cells are inhibited by exposure to MPA.  In 
one study the investigators found that  immature human DCs exposed to MPA were 
induced to a mature phenotype yet  showed a decreased allogeneic  T cell  activation 
through both the direct and indirect pathways (72).  Another study suggested that MPA 
was able to decrease the functional maturation of dendritic cells, finding both decrease 
maturation markers as well as functional decreases in inflammatory cytokine production 
(73).  As dendritic cell trafficking to lymph nodes for antigen presentation is an important 
aspect  of  the  development  of  the  acquired  immune response,  one  group  has  been 
looking at the affects of MPA on dendritic cell trafficking in blood samples taken from 
healthy  human  volunteers.   They  found  that  MPA  decreased  the  expression  of 
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chemokine receptor 7 (CCR7) and increased the expression of CCR1 (upon maturation 
DCs suppress CCR1 and switch to increased expression of CCR7) which correlated with 
a  decrease  in  DC  homing  to  lymphatic  tissues  (as  CCR7+  cells  are  drawn  by 
chemotactic  gradient  towards  lymphatic  tissues)  thus  inhibiting  a  crucial  step  in  the 
initiation of an alloimmune response.  They also found a generally immature phenotype 
of DCs treated with MPA, impaired activation via TLR3 ligation and decreased T cell 
activation via MLR (74).   
Our results examining cytokine production indicated that our DCs after treatment 
with  MPA and MPA-loaded particles  could be involved in  the down-regulation of  the 
immune response.  We found decreases in IL-6 and IL-12 in our free MPA, and nano-
MPA treatments  after  stimulation  with  LPS  consistent  with  the  literature  showing  a 
decrease  in  inflammatory  cytokines  produced  by  DCs  after  treatment  with  MPA. 
Similarly to our study, Lagaraine et al. and Mehling et al. also found decreases in IL-12 
production  by their DCs treated  with MPA.  As IL-6 production has been shown to 
require p38MAPkinase (75), and p38MAPkinase has been shown to be inhibited by MPA 
(76), our decrease in IL-6 that we found is understandable.  Consistent with this as well 
were our results showing decreased IL-2 production in our MLR supernatants in the 
groups with DCs pretreated with MPA and MPA-nanoparticles, which was also consistent 
with the decrease in proliferation via MLR that we found in these treated groups.
Similarly to Lagaraine et al., after culturing DCs with MPA loaded nanoparticles 
we did not find a shift to an immature phenotype as we found no differences in surface 
MHC, CD80 or  CD86 expression via  flow cytometry either  ex vivo  or  in  vitro.   Our 
collaborators  in  Dr  Fahmy's  laboratory,  however,  while  using  a  similar  nanoparticle 
(modified from our PLGA particles)  examined coculture with DCs from an early time 
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point starting at day 1 of DC culture and in the MPA-loaded particle group they were able 
to find a shift  in the maturity phenotype to an immature form with decreased surface 
expression  of  CD40,  CD80 and CD86 (unpublished data).    As  their  particles  were 
slightly different in structure from ours and they started incubation at Day1 instead of 
Day3 or Day5 like we did in our experiment, the change that they found may be due to 
either of these factors and we are planning on recapitulating the data using an earlier 
time point for culture.  Our  ex vivo  data are difficult to compare with the  in vitro  data 
obtained by other investigators.  Our results however are similar to Lagaraine et al. who 
found decreased activation with MPA treated DCs (similarly to us) but in the context of a 
mature phenotype (72).  The difference in maturity phenotype may be related to the time 
point  of  DC exposure to MPA.  Lagaraine et  al.  similarly to our study did not  begin 
exposure of DCs until  5+ days after beginning the culture, and they did not find any 
change in maturity phenotype.  However, both Mehling et al. and Cicinnati et al. found an 
overall decrease in DC maturity but both of their studies cultured their DCs with MMF or 
MPA from day one of DC culture (73) (74).  Consistent with the literature, the difference 
in our results are likely explained by the timing of the treatment, but we would need to 
repeat the in vitro study to determine if this is in fact true.
Overall,  the literature indicates that  MPA pushes the immune system towards 
decreased  immunity  through  interactions  not  just  with  T  and  B  cells  but  through 
interactions  with  antigen  presenting  cells  causing  decreased  antigen  presentation, 
decreased  direct  and  indirect  alloimmunity,  decreased  APC  function  and  increased 
overall  graft  acceptance.  It  remains unclear however the mechanism by which MPA 
exerts these effects on DCs.  As MPA inhibits IMPDH, this has been examined as a 
possible pathway within the DCs.  One group found that MPA decreased p38MAPKinase 
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by  25%  (DC  maturation  is  highly  dependent  on  p38MAPK).   However,  exogenous 
guanosine  failed  to  reverse  the  effects  of  MPA in  DCs  leading  the  researchers  to 
speculate  that  MPA exerted  its  effects  on  DCs  independent  of  IMPDH  (76).   The 
mechanism however remains elusive.
Regulatory T cells
Regulatory T cells (Tregs) are a group of T cells that have an immunomodulatory 
role in the development of antigen-specific immune responses.  There was initially a 
great deal of controversy as to to existence and role of Tregs after early research in the 
1970's led to their suggestion (77).  In the early 1990's however, a group found that the 
observed transplantation tolerance in their study could only be due to Treg involvement 
(78).  This paper furthered the idea of  “infectious” tolerance that had been suggested by 
Gershon et al. in 1971, and Qin et al.  found that the transfer of CD4 T cells from tolerant 
mice were able to induce tolerance in naive lymphocytes and that these newly tolerant 
lymphocytes were able to subsequently induce tolerance in another naive group; hence 
their  “infectious” nature  (78).   This work has since caused an explosion in  research 
looking at Tregs with much focus on Tregs in transplantation.  The most recognized and 
best  studied  group  of  Tregs  are  “natural”  Tregs  produced  in  the  thymus  that  are 
CD4+CD25+ and express Foxp3 which is a transcription factor that is essential to Treg 
growth and differentiation (79).  The development of CD4+CD25+ Tregs has been shown 
to be dependent upon the cytokines IL-10  (80) and TGF-beta  (81).  Tregs appear to 
modulate transplant rejection with their ability to induce antigen specific tolerance, with 
upregulation of CD4+CD25+ T cells that are specific to alloantigen decreasing the graft 
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specific immune response (64).  Multiple pathways have been explored to determine the 
nature of this interaction and DCs appear to both affect and be affected by Tregs (71). 
DCs  have  been  shown  to  be  capable  of  expanding  Treg  CD4+CD25+  positive 
populations  (82) and Tregs have been shown capable of  decreasing maturation and 
functionality of DCs (83).  
There  has  also  been work  looking into the  interaction  of  MPA and DCs with 
Tregs.  One study using porcine dendritic cells found low expression of B7 costimulatory 
molecules,   low  levels  of  IL-12  production  and  generally  weak  proliferative  mixed 
lymphocyte  reactions  when DCs were  cocultured with  peripheral  blood mononuclear 
cells  (PBMC's).   They also found that  after  multiple exposures to MPA treated DCs, 
PBMC's inhibited the alloproliferative response likely indicating an induction of Treg cells 
capable of modulating the alloimmune response  (84).  Another study has shown that 
DCs treated with MPA increased the antigen specific Treg population possibly increasing 
the level of tolerance to antigen specific responses (85). 
As the literature also suggests that MPA and DCs can contribute to the formation 
of Tregs, we examined this interaction in our model as well.  We looked for expression of 
cytokines that lead to Treg production such as IL-10 (86), but were unable to detect any 
differences in production between groups.  We plan to measure TGF-beta, which is a 
classic  stimulator  of  Treg formation  (86) as well.   Despite no differences in cytokine 
production  in  our  treatment  groups  in  vitro  that  would  push  differentiation  to  Treg 
formation, our flow cytometry data with staining for CD4, CD25 and  Foxp3 showed a 
likely proliferation of Tregs in our MPA treatment groups.  We need to repeat this in more 
mice for confirmation, but the experiment indicates a statistically significant increase in 
fluorescence for Tregs in the CD4-targeted animals, free MPA and non-targeted MPA-
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nanoparticles when comparing mean fluorescence intensities.  It remains unclear why 
we may have an increase in Treg development in the absence of increased cytokines as 
the literature looking at DCs and MPA pushing a Treg phenotype finds a parallel increase 
in IL-10 and TGF-beta (85), but perhaps this difference is due to our testing conditions. 
Our increase in Tregs was found ex vivo roughly three weeks post-transplant, while our 
in  vitro testing  for  cytokine  up-regulation  was  via  MLR,  DCs  treated  with  MPA and 
nanoparticles for 24 hours and a short DC/CD4 co-culture without secondary stimulation 
after  co-culture.   Lagaraine  et  al.  in  2008  found  an  up-regulation  of  Treg  inducing 
cytokines  using  a  5-day  coculture  MLR  with  secondary  re-stimulation  with  anti-
CD3/CD28 as well  as an extended length 4-week coculture, and in both shorter and 
longer experiments the cultures were treated continuously with MPA (85).  Our lack of IL-
10 cytokine expression therefore is not surprising considering the much shorter duration 
of interaction between DCs and CD4's and the decrease in nano-MPA treatment times in 
our in vitro experiments compared with the literature.
Role of PD-1 and PD-1 Ligands
The role of co-stimulation in T cell  activation has been well established in the 
development of the alloimmune response (87).  The CD28:B7 costimulation is the most 
well understood of these co-stimulatory interactions and has been shown to be involved 
in  the  initiation  of  T cell  responses  (88)(89).   To counter-balance  these  “excitatory” 
signals, the body has the ability to negatively co-stimulate as well.   CTLA-4 which is 
induced after T cell activation also binds to B7 on APCs and has been shown to be an 
important inhibitor of T cell function (90).  The role of CTLA-4 is exhibited dramatically in 
animals  that  are  CTLA-4  knockouts  as  these  animals  die  rapidly  from  massive 
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lymphoproliferation (91).  
Our discovery of up-regulation of B7-DC and B7-H1 in our mice treated with MPA 
loaded nanoparticles was a very intriguing finding.  The programmed death-1 (PD-1) 
receptor is a recently uncovered molecule that exhibits negative regulation of T cells.  It 
is a member of the CD28 family and was cloned from T cells undergoing apoptosis (92). 
Unlike other members of the CD28 family, PD-1 has been found on CD4, CD8, B-cells 
as well  as myeloid  cells,  but  is  especially  prevalent  on activated T cells  (93).   Two 
ligands for PD-1 have been discovered, PD-L1 (B7-H1) and PD-L2 (B7-DC) both in the 
B7 family but distinct from B7-1 and B7-2 that are involved in T cell costimulation.  PD-
L1(B7-H1) has been found on activated APCs such as dendritic cells, monocytes and B 
cells  (94).   Induction of expression on peripheral APCs has been found secondary to 
exposure to inflammatory cytokines, while PD-1 expression is found on predominately 
on activated T cells (95).  Thus, the interaction between this receptor-ligand appears to 
be critical in regulation of effector and memory T cells with local modulation of specific T 
cell responses as sites of inflammation.  
The role of PD-1 in tolerance has also been clearly shown with its expression on 
the placenta during pregnancy and its location in a position that might help facilitate 
protection against the mothers' immune system  (96).  In addition, both PD-L1(B7-H1) 
knockout mice and mice treated with antibody blocking PD-L1 rejected semi-allogeneic 
pregnancies but accepted syngeneic pregnancies (97), further illustrating the importance 
of  the  PD-1  pathway  in  immunogenic  tolerance.   PD-1  has  been  shown  to  be  an 
important  regulator  of  immunity  especially  within  autoimmunity,  with  multiple 
autoimmune  murine  genetic  lines  showing  PD-1  involvement  in  the  development  of 
disease  entities  such  as  lupus,  diabetes,  autoimmune  cardiomyopathy  and 
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encephalomyelitis (98)(99)(100)(101).   
The PD-1 pathways has  been strongly  implicated in  modulation  of  the  T cell 
response.   In  one  study  examining  PD-1  involvement  in  heart  graft  rejection,  PD-1 
appeared  to  down-regulate  alloreactive  T cells.   The  same study  also  showed  that 
blockade of PD-L1 (B7-H1) increased the speed of allograft rejection, further solidifying 
the role  in  T cell  modulation  (102).   In  another  study by this  same group using an 
adoptive transfer of T cells antigenically specific to the mutated MHC class II molecule I-
Abm12 (our B6.H-2bm12 mice), they found that PD-L1(B7-H1) blockade enhanced T cell 
proliferation, inhibited allospecific T cell apoptosis and skewed the response to a Th1 
phenotype  (103).   PD-1 has also been implicated with Tregs,  as one study found a 
decrease in Treg numbers in PD-L1(B7-H1) knockout mice (104).  Another study found 
that  blockade  of  the  PD-1:PD-L1(B7-H1)  pathway abrogated  Treg  immunoregulation 
suggesting  that  the  pathway is  necessary  for  Treg  function  and  upregulation  (105). 
Recently, a group in Boston demonstrated that PD-L1(B7-H1) has a pivotal role in the 
regulation  of  induced  Treg  development  as  well  as  the  maintenance  of  the  Treg 
response.  They found that PD-L1 (B7-H1) knockouts are only able to minimally induce 
Tregs, and that PD-L1(B7-H1) coated beads are able to induce Tregs.  In addition they 
found  that  PD-L1(B7-H1)  increases  the  expression  of  Foxp3 and  sustains  the 
immunosuppressive function of the cells, clearly implicating PD-1 and its ligand B7-H1 
as centrally important in Treg maintenance and function (106).  Numerous other studies 
have also  implicated PD-1 as  an  important  part  in  the  upregulation  of  Tregs.   This 
connection is intriguing within our study as we have found both an increase in Tregs, as 
well as an upregulation of the PD-1 ligands B7-DC and B7-H1 in our nano-MPA treated 
groups.  The literature strongly supports a connection between these separate findings 
Kassis, Elias                                                                                                           Page 77
and our  graft  rejection  phenotype may be due to  both  an upregulation  of  the PD-1 
pathway through enhanced expression of the PD-1 ligands B7-DC and B7-H1 with a 
possible  subsequent  Treg  proliferation.   Despite  this  information  however,  it  is  not 
completely clear how PD-1 and the PD-1 ligands regulate T cell function, and is likely not 
through a single pathway, but through a  combination of apoptosis, induction of anergy 
and immunoregulation.  
Interestingly, evidence is building that the PD-1 receptor is not the only receptor 
involved in the effects of the PD-L1, and binding effects may be more wide spread.  In 
vivo blockade of PD-1 results in different effects then blockade of PD-L1.  Sandner et al. 
showed that  blockade of PD-L1 significantly decreased the amount  of apoptosis,  but 
blockade  of  PD-1  failed  to  decrease  the  apoptosis  response  (103).   Another  study 
suggested that PD-L1 in tumor cells was able to induce apoptosis of T cells specific to 
the tumor in a non-PD-1 mediated manner (107).  Uncovering these other receptors may 
be valuable in further understanding how the PD-1 ligands B7-H1 and B7-DC are fully 
involved with modulating the immune response.  
PD-1 and MPA
Recently,  a  group  published  a  report  uncovering  a  connection  between  the 
programmed death ligand system and treatment with MPA (108). They observed that the 
PD-1:PD-L interaction in T cells inhibits cytokine production, proliferation and results in 
cell cycle arrest.  They also observed that the affect of MPA on dendritic cells was similar 
and hypothesized that  this  novel  receptor-ligand interaction might  be involved in  the 
behavior seen in DCs treated with MPA.  In agreement with previous work, they found 
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that MPA decreased the allostimulatory behavior of DCs in a dose dependent manner. 
They  also  found  a  down-regulation  of  costimulatory/maturation  molecules  including 
MHCII,  CD80  and  CD86  also  consistent  with  previous  reports,  and  they  found  a 
decrease in Th1 profile cytokines (108).  This decrease in maturation markers with the 
early  treatment  of  DCs  with  MPA  is  consistent  with  the  results  found  by  other 
investigators that  treated DCs with MPA early in their  growth  (73) (74).  Interestingly, 
Geng et al. also made the novel finding that MPA treated DCs upregulated PD-L2 (B7-
DC) also in a dose dependent manner, without any difference seen in PD-L1 (B7-H1) 
(108).   While  this  finding  does  not  prove  causation,  it  certainly  suggests  possible 
involvement of the PD-1 inhibitory pathway in the observed effects of MPA on DCs and 
their role in modulation of T cell activation.   In related studies, it has been reported that 
MPA affects  MAPkinase pathways independent  of  IMPDH pathways in  DCs  (76).   A 
different  group found that  PD-L2:PD-1 interaction  upregulated MAPkinase in  T cell's 
(109).  Therefore, the interactions between the MAPkinase pathways, PD-1 and MPA, 
may be an interesting avenue of exploration to determine the connection between MPA 
and PD-1.
Our findings showing up-regulation of B7-DC and B7-H1 in our MPA-nanoparticle 
treated dendritic cells are therefore consistent with the results of Geng et al. and the 
delay in transplant rejection that we found in our non-targeted group may be due in part 
to the up-regulation of these negative co-stimulatory molecules secondary to the effects 
of the MPA nanoparticles.  We also found a small increase (not significant) in apoptosis 
and  cell  death  with  flow cytometry  staining  for  annexin  and  7-AAD,  although  these 
results would need to be repeated to determine if they are consistent, significant and not 
an artifact of the particles themselves (as empty particles also showed an increase in 
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this population).  However, if this increase apoptosis is real, it may be secondary to the 
MPA treatment  as  it  has  been  suggested  in  previous  studies  that  found  increased 
apoptosis  in DCs treated with MPA  (110)(72).   It  remains unclear the mechanism of 
action  that  may  cause  induction  of  apoptosis  as  MPA may  affect  both  the  IMPDH 
pathway and other unknown pathways (76).  However, increased apoptosis may also be 
through the B7-DC and B7-H1 pathways, as these have also been shown to be involved 
in the induction of apoptosis in other immune cell types (107).  Overall, the expression of 
PD-L1 (B7-H1) on a dendritic cells appears to be a functionally relevant and important 
pathway in the development of tolerance to transplantation (71), and its interaction with 
immunosuppressive  medications  and  use  to  induce  transplant  acceptance  will  be  a 
valuable direction for further research .
Role of Nanoparticles in Transplant
Much of the research investigating nanoparticle modulation of transplant rejection 
by other investigators has limited translatability and comparability to our study, as the 
models  that  other  studies  have  employed  are  dramatically  different  from  skin 
transplantation.  The corneal transplant models used by multiple researchers looking at 
encapsulated tacrolimus, sirolimus and cyclosporine are generally avascular,  and are 
likely very different in physiology from other transplantations.  It is difficult therefore to 
extrapolate from these studies to other forms of transplantation. The susceptibility of T 
cell mediated transplant rejection has been shown to be very different depending on the 
type  of  graft  tissue  and  the  location  of  the  graft  placement  (111).   Indeed,  corneal 
transplants  and  skin  transplants  represent  the  extreme  ends  of  allogenicity  and 
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immunogenicity.  It has been shown countless times in the C57BL/6 – BALB/C model 
that mice will rapidly reject their skin transplants over the course of 1-2 weeks, and that 
this  rejection  is  only  moderately  modifiable  with  general  resistance  to  transplant 
modification treatments.  Skin allografts are therefore considered the most immunogenic 
of all transplanted tissues (16).  
In  contrast,  the  corneal  transplant  in  these same mice  is  very well  tolerated 
without any treatment, and roughly 50% of grafts are spontaneously accepted, with the 
remaining grafts slowly rejected over 8-10 weeks.  Furthermore, this slow rejection is 
easily  modifiable  using  immunosuppressive  agents  (16).   This  sensitivity  to 
immunosuppressive  agents  may  be  due  to  the  fact  that  the  cornea  itself  is  poorly 
immunogenic and the eye is a site of immune privilege (112).  It has been shown in a 
study comparing skin and corneal transplants that the skin transplants reject through 
both direct and indirect pathways by both CD4+ and CD8+ cells activated against both 
MHC and minor antigens.  Corneal transplants however, only reject via CD4+ T cells that 
are indirectly activated against minor histocompatability antigens (16).  If Schenk et al. 
are correct that our  B6.H-2bm12 mice reject through only a direct pathway (62), then 
the skin transplants used in our study would respond in a dramatically different fashion 
from a corneal transplant.
The comparison of our research to the work of Alemdar et al. using dopaminergic 
CNS transplantations (55)(56), exhibits similar problems for relation to our study as the 
corneal transplant research.  The central nervous system is also an immune privileged 
site similarly to the eye (113) and transplant rejection and tolerance is likely mediated by 
factors that are different from the highly immunogenic allogenic skin graft.   The CNS 
produces  a  number  of  anti-inflammatory  molecules  which  decrease  the  overall 
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inflammatory response  (113).   MHC expression on resident  immune cells  has  been 
shown to be relatively low, decreasing T cell activation and proliferation.  The blood brain 
barrier maintains this protection so despite its vascularization it  is relatively protected 
from the rest of the body (113).  Overall it is difficult to determine the applicability of the 
findings  of  Alemdar  et  al.  compared  with  our  system  because  of  both  the  type  of 
transplanted tissue as well  as their  use of  liposomal  particles (not  PLGA like in  our 
study).
The comparisons to these other models illustrates a potential  limitation of our 
work in translation to clinical allografts.  Similarly to the difference between rejection of 
corneal and CNS transplant and skin transplants, the biology of skin graft rejection may 
also be different from solid organ vascularized grafts used clinically such as the heart, 
kidney, lung and liver.  Skin appears to be the most immunogenic transplanted graft, with 
lung  and  small  bowel  also  causing  a  robust  immune  response.   In  decreasing 
immunogenicity  are  pancreatic  islets,  vascularized  pancreas,  heart,  kidney and  liver 
transplants (114) (111).  Liver allografts are sufficiently non-immunogenic to be accepted 
without treatment in many animal models  (115).  Our model with skin allografts which 
initiate  the  most  robust  immune  response  may  therefore  not  represent  the  same 
response  that  might  be  seen  in  other  tissues.   In  skin  transplants  which  are  not 
vascularized,  the histologic  findings of  acute and chronic  rejection  involving  immune 
invasion and deposition within the vascular walls will not be found.  Non-vascularized 
grafts  are  also  more  susceptible  to  ischemic  damage  (116) leading  to  non-specific 
inflammation and necrosis which may allow the graft to become more affected by the 
targeted  immune  response.   This  increased  sensitivity  however  has  been  largely 
dismissed as evidence has mounted that vascularized skin grafts also reject with similar 
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intensity  as  non-vascularized  grafts  (111).   The  mechanism  behind  the  increased 
immunogenicity  of  skin  allografts  remains  unclear  but  other  possibilities  have  been 
proposed including the presence of tissue specific antigens in the skin.  The skin also 
serves as an immunologic barrier and thus has large numbers of dendritic  cells with 
subsequent ability to robustly activate alloreactive T cells.   Recent work showed that 
highly immunogenic skin grafts tend to require a lower number of effector T cells for 
rejection when compared to other solid organs like heart transplants (69)(62).  
The work that is most directly comparable to our study was done by McAlister et 
al. who used liposomal tacrolimus to treat both skin allografts and heart allografts.  They 
compared oral free vs oral liposomal drug and found improved skin graft survival with the 
liposomal formulation and unchanged survival of the heart allograft (58).  Ultimately, this 
study is also difficult to compare with our own because this study delivered drug orally 
and used liposomal particles instead of PLGA particles, but overall it is in agreement with 
our results finding that nanoparticle encapsulated drug can be superior to free drug in 
highly immunogenic skin transplantation.  
Due to these differences in graft behavior, future studies could move to one of 
two models that we have had experience with in our lab.  The pancreatic islet transplant 
is  less  immunogenic  and  technically  can  be  done  with  relative  ease.   Our  lab  has 
recently  started  using  this  model  in  aging  studies  (unpublished  data),  and  this  less 
immunogenic model might be able to tease out differences between CD4-targeting and 
non-targeted nanoparticles that we were unable to see in our skin graft model.  An even 
greater  improvement  to  our  model  would  include using vascularized heart  allografts. 
These transplants require far more technical expertise, surgical skill and time than the 
skin transplants we are currently employing, but this model would represent a human 
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solid  organ  transplantation  much  better  than  either  a  skin  or  pancreatic  islet 
transplantation.  We have had some experience in our lab with these transplants as well 
(117), and perhaps this would be a worthy future direction to consider.  
Another area that would further strengthen the argument for use of nanoparticles 
in transplantation modulation would be to study targeting of nanoparticles encapsulated 
with other drugs such as tacrolimus, sirolimus and cyclosporine.  Mychophenolic acid is 
an effective drug that has largely replaced azathioprine, but it is generally only used in 
combination with other medications as maintenance therapy, is rarely used alone and 
rarely for induction of immunosuppression  (21).  MPA is generally taken orally as the 
pro-drug mycophenolate mofetil and is actually fairly well tolerated compared with many 
other immunosuppressive medications.  Therefore, MPA may not ultimately be the best 
drug for this technology to be used with.  Multiple groups have had success already with 
rapamycin  (49) cyclosporine  (52)(50) and  tacrolimus  (53) encapsulation  in  PLGA 
particles  for  use  in  corneal  transplants.   Our  collaborators  have  indicated  that 
encapsulation of these drugs would be possible in their laboratory as well and this may 
present another interesting future approach to our work.  
As  clinically  used  immunosuppressives  are  given  orally,  it  would  also  be 
interesting for us to develop an oral form of targeted nanoparticles.  Oral formulations 
may be preferential in terms of compliance, ease of use and ability to treat away from a 
hospital  or  clinic.   Using  oral  nanoparticles  would  be  superior  to  using  intravenous 
treatments, and this would be a valuable direction to take our research in the future. 
Oral  preparations  of  liposomal  drugs  have  been  used  to  many  years  (doxirubicin, 
vincristine, amphotericin), and McAlister et al. even looked at oral liposomal tacrolimus 
(58),  but  there  has  been  little  work  looking  at  oral  PLGA  encapsulation  of 
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immunosuppressive  drugs.   One group  has  used  PLGA particles  encapsulated  with 
cyclosporine as an oral treatment (40).  Cyclosporine, due to its high molecular weight, 
rigid structure and the P-glycoprotein intestinal cellular efflux mechanisms (P-gp efflux) 
present in the GI system causes overall low bio-availability with oral intake.  Nanoparticle 
encapsulation  bypasses the  P-gp  efflux,  decreases  gastrointestinal  tract  degradation 
and  gut  wall  metabolism  and  improves  pharmacokinetic  profiles  and  bio-availability. 
Nanoparticles can also allow protection from first pass liver metabolism as happens with 
traditional oral drugs  (40).  This group found that nephrotoxicity was decreased in the 
nanoparticle  group  and  that  the  nanoparticle  formulation  exhibited  consistent  and 
controlled slow release with better bio-availability and intestinal uptake (40).  These data 
indicate that PLGA particle oral formulations may have a viable future in transplantation 
and that it may be interesting to use oral formulations of MPA loaded particles in our 
transplant model.
Conclusion
Despite the little previous research that has been done looking at nanomedicine 
in transplant, it appears that this field has great potential and that nanoparticles will likely 
be an important avenue for the improvement of drug delivery.  The medical management 
and treatment of  patients post-transplantation is currently limited by the efficacy and 
dose-toxicity  of  the  currently  available  immunosuppressive  medications.   With  the 
considerable expense of developing new medications, the possibility of encapsulation of 
currently  used  drugs  in  nanoparticles  with  improved  pharmacokinetics,  local  drug 
delivery and improved side effects make this avenue an attractive option.  A bright future 
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of medicine lies in targeted therapies that deliver drug locally to specific tissues or cell 
types  and  spare  the  rest  of  the  body  from  the  deleterious  effects,  and  targeted 
nanoparticles will  likely be part  of this future.  Our research sets the stage for these 
therapies as our work is the first antibody or ligand targeted nanoparticle research in a 
transplant  model.   Our  work  suggested  that  targeted  and  non-targeted  MPA-loaded 
particles are both capable of increasing graft survival at thousand-fold lower doses  in 
vivo, and that MPA-loaded particles decrease lymphocyte proliferation with MLR, finding 
possible differences in efficacy of targeting dependent upon the immunogenicity of the 
model.   We also found that  targeting particles likely show specificity to CD4 T cells. 
Furthermore, we examined the mechanistic effects of our particles within our model with 
results suggesting dendritic cell involvement with uptake of MPA-loaded particles and 
subsequent  decrease  in  the  alloimmune  response  with  up-regulation  of  Tregs, 
upregulation of the inhibitory costimulatory molecules B7-DC and B7-H1, and decreased 
inflammatory  cytokines  with  MPA-loaded  nanoparticles.   Overall  our  research  is  a 
starting point to develop further clinically relevant nanoparticle-drug combinations, and 
further  uncover  and  investigate  the  basic  pathways  and  interactions  underlying 
nanoparticle modulation of the transplant immune response.   
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